**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 65487

**Manuscript Type:** REVIEW

**Review of the potential of mesenchymal stem cells for the treatment of infectious diseases**

Sharma A *et al*. MSCs for infectious diseases

Amit Sharma, Anuja Chakraborty, Bithiah Grace Jaganathan

**Amit Sharma, Anuja Chakraborty, Bithiah Grace Jaganathan,** Stem Cell and Cancer Biology Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 781039, India

**Author contributions:** Sharma A wrote the manuscript; Chakraborty A wrote the manuscript; Jaganathan BG conceptualized the study and wrote the manuscript; All authors have read and approved the final version of the manuscript.

**Corresponding author: Bithiah Grace Jaganathan, PhD, Associate Professor,** Stem Cell and Cancer Biology Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Amingaon, Guwahati 781039, Assam, India. bithiahgj@iitg.ac.in

**Received:** March 8, 2021

**Revised:** April 7, 2021

**Accepted:** June 3, 2021

**Published online:** June 26, 2021

**Abstract**

The therapeutic value of mesenchymal stem cells (MSCs) for the treatment of infectious diseases and the repair of disease-induced tissue damage has been explored extensively. MSCs inhibit inflammation, and reduce pathogen load and tissue damage encountered during infectious diseases through secretion of antimicrobial factors for pathogen clearance and phagocytose certain bacteria themselves. MSCs dampen tissue damage during infection by downregulating the levels of pro-inflammatory cytokines and inhibiting the excessive recruitment of neutrophils and proliferation of T cells at the site of injury. MSCs aid in the regeneration of damaged tissue by differentiating into the damaged cell types or by releasing paracrine factors that direct tissue regeneration, differentiation, and wound healing. In this review, we discuss in detail the various mechanisms by which MSCs help combat pathogens, tissue damage associated with infectious diseases, and challenges in utilizing MSCs for therapy.

**Key Words:** Infectious diseases; Mesenchymal stem cells; Antimicrobial effect; Immunomodulation; Tissue repair; COVID-19

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

Sharma A, Chakraborty A, Jaganathan BG. Review of the potential of mesenchymal stem cells for the treatment of infectious diseases. *World J Stem Cells* 2021; 13(6): 568-593 URL: https://www.wjgnet.com/1948-0210/full/v13/i6/568.htm DOI: https://dx.doi.org/10.4252/wjsc.v13.i6.568

**Core Tip:** This review discusses the therapeutic benefits of utilizing mesenchymal stem cells (MSCs) to treat infectious diseases and repair tissue damage induced by the disease-causing infectious agents. The immunomodulatory and regenerative properties of MSCs are modulated by the inflammatory milieu generated by the disease and should be considered while utilizing MSCs for treatment.

**INTRODUCTION**

Infectious diseases are a leading cause of morbidity and mortality worldwide; respiratory infections and pneumonia are among the major causes of death globally. Failure of commonly used therapies and drugs and the rising number of new infectious disease outbreaks have increased the necessity to identify novel therapeutic strategies to combat infections and the resulting organ and tissue damage associated with the diseases. Mesenchymal stem cells (MSCs) are non-hematopoietic cells found in the bone marrow and other tissues such as adipose tissue, placenta, dental pulp, synovial membrane, endometrium, umbilical cord blood, Wharton's jelly, and ocular tissues[1-4]. Tissues are mechanically or enzymatically dissociated to isolate MSCs, giving rise to plastic adherent cell populations[5]. MSCs can also be separated by flow cytometry sorting based on their cell surface marker expression[6,7]. MSCs possess extensive self-renewal, proliferative, and multilineage differentiation potential. They are identified based on the expression of cell surface markers cluster of differentiation 105 (CD105), CD90, CD73, CD 44, CD29 and are negative for markers such as CD45, CD34, CD14, CD11b, CD79α, CD19, and human leukocyte antigen (HLA)-DR[1]. However, when stimulated with interferon-gamma (IFN-γ), MSCs express HLA-DR[8-10].

MSCs have multilineage differentiation ability and give rise to adipocytes, osteoblasts, and chondrocytes under standard differentiation conditions. Additionally, MSCs play an important role in tissue repair and homeostasis; thus, they have become an attractive therapeutic option for the treatment of several infectious and degenerative diseases[11-17]. In addition, MSCs possess immunomodulatory and immunosuppressive properties, reduce inflammation, and display immune protective functions[1,18,19]. Due to the rising number of infectious diseases and associated organ damage, MSCs have been explored as a possible treatment option in recent years. Several pre-clinical and clinical trials with MSCs have yielded encouraging results, improved therapeutic outcomes, and provided the opportunity to utilize MSCs for the treatment of infectious diseases in addition to existing therapeutic options. Further, intravenous administration of MSCs is effective in treating pathogen-induced organ damage in several disease models[20-22].

This review summarizes various studies that tested the therapeutic advantages of MSCs in treating infectious diseases and repairing disease-induced tissue damage. We also discuss the various modes in which MSCs function to clear pathogens and rebuild the damaged tissue, the signaling pathways modulated by MSCs in the host cells during infections, and finally, some of the challenges associated with utilizing MSCs for therapy.

**Methodology**

The objective of this review was to analyze various pre-clinical and clinical studies that utilized MSCs for the treatment of infectious diseases and associated tissue damage. PubMed, Scopus, and Web of Science databases were searched without any language restrictions. Studies that utilized MSCs with or without modification in disease models of infection or pathogen-induced tissue damage were selected for inclusion in the review. The research articles were grouped as follows based on their major findings when MSCs were injected: direct anti-pathogen effects, immunomodulatory effects, differentiation into cells of target tissues, and clinical trials.

**Direct antimicrobial effects of MSCs**

Several studies have reported that administration of MSCs during lung injury and sepsis significantly reduce the bacterial load. MSCs secrete four types of antimicrobial peptides (AMPs): LL-37, hepcidin AMP (HAMP), lipocalin 2 (LCN2), and beta-defensin-2 (BD2) (Figure 1). Besides AMPs, several other paracrine factors secreted by MSCs also contribute to the antimicrobial defense. LL-37 is an amphipathic AMP that belongs to the cathelicidin family of AMPs that induces bacterial lysis and enhances antibiotic sensitivity. LL-37 directly binds to and inactivates lipopolysaccharides (LPS), thereby disrupting the bacterial outer membrane. LL-37 can also neutralize the LPS (endotoxin) released by bacteria. LL-37 also has chemotactic activity to recruit immune cells to enhance pathogen clearance at the site of infection. However, this recruitment of immune cells such as macrophages does not increase pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α)[23,24]. LL-37 also promotes regeneration and angiogenesis by binding to formyl peptide receptor-like 1 expressed on endothelial cells[25]. LL-37 secreted by either bone marrow-derived MSCs (BM-MSCs) or adipose tissue-derived MSCs (AD-MSCs) increased the effectiveness of antibiotics, enhanced pathogen killing, and slowed bacterial growth in a pulmonary infection model of cystic fibrosis induced by *Pseudomonas aeruginosa*, *Staphylococcus aureus,* and *Streptococcus pneumonia*[26]. HAMP, another AMP secreted by MSCs, promotes bacterial clearance by preventing iron uptake by the pathogens. HAMP promotes transport of the cellular iron storage protein, ferritin, into the macrophages and subsequent destruction in lysosomes. This causes iron to be stored inside the macrophages, making it unavailable for bacterial survival. So, by depleting iron, HAMP hampers the growth and survival of bacteria[27]. LCN secreted by MSCs also promotes bacterial clearance by blocking iron uptake by the bacterial cells[28,29]. BD2 secreted by MSCs reportedly plays an important role in pathogen clearance. Sung *et al*[30] reported that in an *Escherichia coli-*induced pneumonia model, intratracheal administration of human umbilical cord-derived MSCs (UC-MSCs) resulted in the attenuation of lung injury and led to a significant reduction in inflammation and increase in bacterial clearance from the infected site. Microarray analysis found that toll-like receptor 2 (TLR-2), TLR-4, and BD2 expression levels were significantly upregulated in lung tissue. The TLR-4 signaling pathway is important for BD2 secretion and silencing of TLR-4 but not TLR-2 abolished the anti-bacterial effect of MSCs against *E. coli*[30]. Depletion of the essential amino acid, tryptophan, by indoleamine 2,3-dioxygenase (IDO) secreted by MSCs also has antimicrobial effects on various pathogens such as toxoplasma, plasmodium, chlamydia, rickettsia, streptococci, staphylococci, and herpes virus[31]. In addition, MSCs directly phagocytose bacteria through scavenger receptors (Figure 1). Khan *et al*[32] found that human MSCs internalized *M. tuberculosis* through two types of scavenger receptors, namely the macrophage receptor with collagenous structure and scavenger receptor class B member 1. These endocytosed mycobacteria were killed by activation of intrinsic autophagy and nitric oxide secreted by MSCs[32].

In addition to the anti-bacterial properties, MSCs also exert anti-viral effects. Rodrigues *et al*[33] found that MSCs had suppressive effects on human T-lymphotropic virus (HTLV)-infected T cells, similar to that seen with healthy T cells. IDO and prostaglandin E2 (PGE2) secreted by MSCs suppressed the proliferation of infected T cells, and the co-culture of infected T cells with MSCs reduced the expression of HTLV1 *pol* gene[33]. In a mouse model of lethal herpes simplex virus (HSV-1) infection, MSC administration significantly increased the survival percentage and exerted anti-viral effects by upregulating IFN-γ levels, while decreasing IL-6 and TNF-α serum levels[34].

**MSCS in immunomodulation**

MSCs reduce the infiltration and accumulation of neutrophils and other immune cells at the site of tissue damage and infection. Neutrophils constitute the first line of defense against infections, but their excessive accumulation at the site of infection results in increased secretion of various proteolytic enzymes, matrix metalloproteinases, reactive oxygen species (ROS), and pro-inflammatory cytokines leading to neutrophil extracellular traps (NETosis). Although NETosis helps in pathogen clearance, it also results in tissue damage due to the exaggerated inflammatory response[35]. Excessive NET formation and its poor degradation results in tissue damage and has been implicated in sepsis[36,37] and coronavirus disease 2019 (COVID-19)[38]. Furthermore, MSCs alleviate the excessive influx of neutrophils through TNF-α-stimulated gene-6 (TSG-6) secretion, which inhibits the recruitment of neutrophils by IL-8[39]. In addition, MSCs diminish NET formation by delaying the apoptosis of neutrophils and inducing intercellular adhesion molecule 1 expression in neutrophils to facilitate their phagocytosis[40]. MSCs also control the tissue damage caused by toxic reactive oxygen and nitrogen species produced by neutrophils through the secretion of antioxidant enzymes such as superoxide dismutase (SOD)[40].

MSCs regulate the function of macrophages during infection. Macrophages play an important role in mediating the inflammatory response and might exist as pro-inflammatory M1-type, which mounts the immune response against pathogens, and anti-inflammatory M2-type, which helps in resolving inflammation through secretion of anti-inflammatory cytokines[41]. However, during acute respiratory distress syndrome (ARDS), the M1 phenotype is upregulated, disrupting the balance between M1 and M2 macrophages[42]. Several studies have reported that MSCs moderate the inflammatory response by promoting the polarization of macrophages towards M2 phenotype through secretion of various factors such as IL-1 receptor antagonist[43], decorin[44], stanniocalcin-2[45], and TSG-6[12]. In an LPS-induced acute lung injury (ALI) model, transforming growth factor-β3 (TGF-β3) and thrombospondin 1 (TSP-1) secreted by dental follicle-derived MSCs upregulated M2 phenotype in alveolar macrophages, marked by the increased expression of enzyme arginase 1 and downregulation of M1 macrophage markers such as inducible nitric oxide synthase and CD86[46]. Conversely, co-culture of rat BM-MSCs with LPS-treated alveolar macrophages promoted the survival of macrophages through the upregulation of anti-apoptotic B-cell lymphoma 2 (Bcl-2) and inhibition of caspase-3 and Bcl-2-associated X protein expression by modulating the Wnt/-catenin pathway[47]. Furthermore, PGE2 secreted by MSCs upregulated the bactericidal activity of M1 macrophages through phosphoinositide 3-kinase and mediated the increase in NADPH oxidase 2 activity and ROS production[41]. Interestingly, in a pre-clinical ARDS model, Jackson *et al*[48] found that MSCs enhanced pathogen clearance and survival of alveolar macrophages by donating mitochondria *via* tunneling microtubules. In addition, intravenous injection of murine BM-MSCs overexpressing hepatocyte growth factor (HGF) attenuated the damage in an LPS-induced ALI model by modulating the function of dendritic cells (DCs). HGF secreted by the MSCs induced mature DCs to differentiate into “tolerogenic” regulatory DCs by activation of the HGF/Akt pathway[49].

Injection of MSCs inhibited the proliferation of septic natural killer (sNK) cells and significantly improved the survival of the experimental animals in a cecal ligation puncture mouse model. Injection of MSCs altered the cytokine profile in the serum and altered the sNK cell function, possibly through modulation of the Janus kinase/signal transducer and activator of transcription (STAT) pathway[50]. In pre-clinical models of acute liver injury and liver necrosis, injection of murine MSCs significantly downregulated the IL-17 level and decreased IL-17-producing NKT cells but enhanced FOXP3+ IL10+ NKT cells[51]. MSCs also suppressed the differentiation of CD4+ T cells into IFN-γ-producing T helper type 1 (Th1) cells or IL-17-producing Th17cells but increased the number of regulatory T cells (Tregs)[52]. In a mouse model of *Aspergillus* hyphal extract-induced inflammation, administration of human BM-MSCs decreased IL-4, IL-5, and IL-17 levels and ameliorated inflammation[53]. In the presence of IFN-γ and TNF-α, MSCs enhanced the secretion of programmed death-ligand 1 (PD-L1) and PD-L2, respectively, which in turn inhibited T-cell proliferation and upregulated FOXO3 expression in these cells[54]. CD200, a cell surface protein highly expressed in Wharton’s jelly-derived MSCs (WJ-MSCs), has been implicated in inducing immune tolerance by interacting with CD200R present on CD4+ and CD8+ T cells[55].

Although MSCs are considered immune privileged, some studies have reported that they are susceptible to NK-mediated killing in an IL-2-dependent manner. Stimulation of TLRs on MSCs leads to shedding of NK cell-interacting ligands such as major histocompatibility complex I (MHC I) and NK group 2 member D, making them less susceptible to killing by activated NK cells[56]. TLR4 stimulation increases the survival of MSCs under stress conditions through the upregulation of extracellular signal-related kinase 1/2 (ERK1/2)[57]. Studies that have tracked MSCs *in vivo* found that MSCs died 24 h post-intravenous injection and accumulated in the lungs and liver[58,59]. de Witte *et al*[58] reported that the *in vivo*-injected UC-MSCs were rapidly phagocytosed by the monocytes, which then expressed PD-L1 and IL-10 and downregulated TNF-α expression, resulting in acquisition of the regulatory phenotype by these monocytes. Furthermore, phagocytosis of UC-MSCs by lung phagocytes induced the production of (C-X-C motif) ligand (CXCL) 9 and CXCL10 by these cells, which helped to recruit CXCR3+ Tregs[60]. Keratinocyte growth factor (KGF) secreted by MSCs promotes the survival of monocytes by enhancing Akt phosphorylation, thereby facilitating bacterial clearance[61]. In a mouse model of Coxsackie virus infection, secretion of CX3CL1 by the injected human BM-MSCs inhibited the migration of pro-inflammatory Ly6Chigh cells but promoted anti-inflammatory LyC6low monocyte migration. By modulating monocyte trafficking to the heart, MSCs reduced inflammation and damage in heart tissue[62]. Treatment with BM-MSCs improved lung function and reduced inflammatory cytokines in H9N2-[63] and H5N1-infected mice[64]. However, treatment with UC-MSCs was more effective than BM-MSCs in restoring alveolar fluid clearance (AFC) and reducing inflammation in H5N1-infected mice[64]. Thus, modulation of immune cells forms the basis for long-term therapeutic effects of MSCs in facilitating pathogen clearance and reducing inflammation-mediated tissue damage (Figure 2).

Several studies have shown that when subjected to an inflammatory environment, MSCs secrete higher levels of anti-inflammatory factors such as TSG-6, IL-10, and PGE2 and inhibit nuclear factor kappa B (NF-B) signaling, which leads to the decreased expression of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β[43,51,65-68]. In the absence of pro-inflammatory stimulus, MSCs secrete low levels of cyclooxygenase 2 (COX2), PGE2, TGF-β1, HGF, IL-10, PD-1, PD-L1, and PD-L2[69]. In contrast, when subjected to an inflammatory environment consisting of TNF-α and IFN-γ, MSCs significantly upregulate the expression of PGE2, COX2, PD1, IDO, HGF, and TGF-β1, which contribute to their immunomodulatory properties[67,69]. Furthermore, in the presence of pro-inflammatory cytokines, MSCs also supplement the production of anti-inflammatory lipid mediator lipoxinA4 (LXA4) by alveolar type II epithelial (AT-II) cells[70]. Secretion of IDO by MSCs, a rate-limiting enzyme involved in the catabolism of tryptophan *via* the kynurenine pathway, has been implicated in MSC-mediated reduction of inflammation[33,71]. Inhibition of IDO with 1-methyltryptophan abolished the anti-inflammatory effects of MSCs on a murine hepatitis model[51], and inhibition of kynurenine, a downstream metabolite of IDO, downregulated TSG-6 secretion by MSCs[71]. Similarly, in an ALI mouse model, the anti-inflammatory effects of MSCs were abolished when TSG-6 or HGF was silenced[20,72], indicating the role of MSC-secreted factors in controlling the inflammation. Additionally, netrin-1 expressed by MSCs inhibited neutrophil migration[73]. LXA4 and PGE2 secreted by MSCs induce heme oxygenase-1 (HO-1) expression in macrophages, resulting in cytoprotection during oxidative stress-mediated inflammation[74,75]. HO-1, along with angiopoietin-1 (Ang1), inhibits the TNF-α stimulated migration of leukocytes[76,77]. Secretion of antioxidants such as SOD, catalase, glutathione peroxidase, and glutathione reductase by MSCs also reduces oxidative stress[78].

Some studies have also identified a pro-inflammatory role of MSCs, in which MSCs promote the migration of neutrophils, macrophages, and monocytes to the infection site and expedite pathogen clearance[79,80]. Petri *et al*[81] found that secretion of IFN-γ by MSCs in the early stages of bacterial infection augmented the function of NK cells but induced the regulatory phenotype in NK cells at the later stages. In a *P. aeruginosa*-induced chronic lung injury model, injection of a high dose of AD-MSCs inhibited bacterial load and downregulated bacteria-induced secretion of PGE2 by alveolar cells[82]. Downregulation of PGE2 levels indirectly enhanced the immune response, leading to higher bacterial clearance[26,83]. Further, injection of BM-MSCs in *Paracoccidioides* *brasiliensis*-infected mice led to increased fungal levels and exaggerated immune responses, with increased accumulation of neutrophils, eosinophils, and M2 macrophages, leading to congestion and edema in lungs[84]. Similarly, treatment with BM-MSCs in mice with latent *M. bovis* infection resulted in significantly higher mycobacterial number and granuloma formation[85]. However, if the MSCs were conditioned with TLR-3 ligand, poly (A:U) prior to the injection, it significantly reduced the pathogen load, suggesting that priming of MSCs was necessary for their anti-mycobacterial effect[85].

**MSCs promote repair of tissue damage**

The regenerative and multipotent differentiation ability of MSCs also aids in the repair of tissue damage caused by infection. Despite employing different therapeutic strategies, the clinical outcome of ALI and acute respiratory distress syndrome is still poor and remains a significant healthcare burden necessitating novel therapeutic interventions[21,86]. Apart from controlling infection and inflammation, the paracrine factors secreted by MSCs repair and regenerate the damaged epithelial and endothelial barriers of the alveoli[64]. In the alveolar region, AT-I and AT-II epithelial cells (pneumocytes) constitute the continuous alveolar epithelium, separated from the endothelium by a layer of connective tissue. KGF and TSP-1 secreted by MSCs induce the proliferation of epithelial cells and induce the differentiation of AT-II cells into AT-I cells, which further promote the regeneration of alveolar epithelium[87,88]. Under normal conditions, tight junctions and other cellular junctions maintain the integrity of cellular barriers, allowing the selective flow of fluid. During ALI/ARDS, however, the barrier becomes compromised, and disruption of the ion channel proteins and aquaporins (AQPs) causes fluid leakage into the interstitium and alveolar spaces resulting in edema and compromised gas exchange in the lungs[89,90]. Transepithelial ion exchange through Na+ ion channels (ENaC), Na+/K+ ATPase, and cystic fibrosis transmembrane conductance regulator (CFTR) present on alveolar epithelial cells creates an osmotic gradient that drives the movement of water required for normal AFC. Inflammatory cytokines such as TNF-α, TGF-β1, IFN-γ, IL-4, IL-13, and IL-1β downregulate the expression of ion channel and junction proteins in the alveolar epithelial and endothelial layer leading to the dysregulation of AFC[91]. Lee *et al*[92] found that KGF secreted by MSCs promotes AFC and ameliorates edema during lung injury. KGF secreted by MSCs upregulates the expression of catalytic α1 subunit of Na+/K+ ATPase and surfactant protein (SP A) in AT-II cells[87]. Also, KGF-silenced MSCs failed to dampen pulmonary edema in an LPS-induced ALI mice model[93].

Furthermore, paracrine factors such as LXA4, KGF, Ang1, vascular endothelial growth factor (VEGF), and HGF secreted by MSCs induce the expression of ion channel, cellular junction, and tight junction proteins in epithelial cells, which facilitate repair of alveolar epithelium and restore normal AFC[68,70,94,95]. In an ALI mouse model, Fang *et al*[70] found that intratracheal administration of MSCs significantly increased LXA4 level in bronchoalveolar lavage fluid (BALF) and improved the survival of the experimental animals. LXA4 was found to enhance CFTR expression in AT-II cells damaged by LPS treatment through downregulation of Akt phosphorylation, which led to improved AFC[96]. LXA4 also increases the expression of α and γ subunits of ENaC channel[97], and AQP5 in LPS-stimulated epithelial cells[98,99], which contribute to enhanced fluid clearance, improved gas exchange, and pulmonary edema resolution during lung injury. LXA4 improves the integrity of the epithelial barrier by upregulating the expression of junction proteins such as zona occludens 1, claudin 1, and occludin[100]. ALI stimulates ROS generation in lung tissue, which induces mitochondria dysfunction, leading to more ROS release, forming a cycle of 'ROS-induced ROS release'[101,102]. LXA4 activates NF-E2-related factor 2, which is important for maintaining the redox balance in epithelial cells and rescues E-cadherin expression[103]. LXA4 increases the proliferation of AT-II cells, reduces caspase-3 levels, and inhibits LPS-induced apoptosis[104]. LXA4 secreted by MSCs reduces the permeability of alveolar epithelium by restoring the expression and distribution of tight junctions (Figure 3). MSCs when co-cultured with AT-II cells in the presence of TNF-α, IFN-γ, and IL-1β had significantly high expression of Ang1, which inhibited NF-κB activation and rescued claudin 18 expression in AT-II cells[64,94]. Ang1 binding increases active Rac1 levels and subsequently leads to the inactivation of Ras homolog family member A (RhoA) in endothelial cells[105]. RhoA activation disrupts actin and myosin contraction and promotes stress fiber formation, thereby increasing the endothelial permeability, whereas Rac1 counteracts RhoA by activating p190GAP and promotes the formation of adherens and tight junctions[106]. Ang1 increases Rac1/2/3 activity and downregulates active RhoA levels in AT-II cells[94] (Figure 4). VEGF and HGF secreted by MSCs reduced endothelial permeability by upregulating the expression of junction protein VE-cadherin, and the silencing of VEGF or HGF in MSCs inhibited their ability to reduce paracellular and transcellular endothelial permeability[107,108]. Yang *et al*[95] reported that HGF and VEGF secreted by MSCs acted synergistically to remodel F-actin, and tight junctions in LPS-stimulated pulmonary endothelial cells by upregulating Rac1 and downregulating RhoA expression.

MSCs were found to enhance the survival of pulmonary epithelial cells, hepatocytes, and cardiac myocytes by enhancing autophagy in several pre-clinical infection models. Autophagy is also associated with reducing inflammatory signals. Hu *et al*[109] reported that LPS stimulation of mouse lung epithelial cells or human bronchial epithelial cells led to downregulation of autophagy marker MAP1LC3B through activation of mammalian target of rapamycin (mTOR) *via* TLR4 signaling. Silencing of mTOR or overexpression of autophagy-related proteins in epithelial cells reduced the production of cytokines IL-6 and IL-8[109]. Chen *et al*[110] found that miR-100 present in human WJ-MSC-derived exosomes (extracellular vesicles, EVs) downregulated mTOR in rat AT-II cells. Treatment with MSC-derived EVs activated autophagy but inhibited apoptosis and secretion of pro-inflammatory cytokines in bleomycin-treated rat epithelial cells through mTOR downregulation[110]. The protective and repair functions of the MSCs were found to be mediated by p70S6K1[111], an isoform of S6K1, which is the downstream target of mTOR[65]. The protective effects of MSCs on injured alveolar epithelial cells are also mediated by the donation of mitochondrial by MSCs to the alveolar epithelial cells. BM-MSCs formed connexin 43 mediated Ca2+ transporting gap junctions[112] and transferred mitochondrial to the alveolar epithelial cells with the help of Miro1, a mitochondrial Rho GTPase[113] (Figure 4). In addition to modulating the inflammatory response, treatment with MSCs significantly reduced collagen deposition, fibrosis, and scar formation in injury models involving various organs such as lungs[114,115], liver[116-118], heart[16], bladder[17] and eyes[119]. The anti-fibrotic effects of MSCs were mediated by upregulation of matrix metalloproteinases matrix metalloproteinase 1 (MMP1), MMP13, MMP14, and inhibition of tissue inhibitors of MMP 1[118,120].

The ability of MSCs to differentiate into different cell types contributes to the repair of damaged tissue during diseases. In LPS-induced ALI models, activation of canonical Wnt signaling promoted differentiation of mouse BM-MSCs into AT II cells and inhibited lung fibrosis[121]. Liu *et al*[122,123] found significantly high levels of Wnt3a in the lung tissue of ALI mice and *in vitro* co-culture of mouse BM-MSCs with AT-II cells of ALI or normal mice in the presence of Wnt ligands induced the differentiation of MSCs into AT II cells expressing AQP5, SPB and SPC. Further, intratracheal transplantation of murine MSCs overexpressing receptor tyrosine kinase-like orphan receptor 2 (ROR2), a Wnt5a receptor, into ARDS mice led to differentiation of MSCs into AT II cells, suppressed LPS-induced inflammation, and significantly improved the alveolar epithelial permeability[114]. However, under non-inflammatory conditions, inhibition of Wnt signaling promoted epithelial differentiation of murine lung resident MSCs (LR-MSCs)[124]. Fang *et al*[125] found that resident Dermo1+ LR-MSCs contributed to various lung epithelial cell types during LPS-induced lung injury. Further, intratracheal administration of fibroblast growth factor 10 (FGF-10) mobilized the LR-MSCs, which were more effective in ameliorating the LPS-induced lung injury in rats compared to BM-MSCs[126] and also promoted the differentiation of MSCs into AT II cells[127]. Silva *et al*[128] showed that LR-MSCs were better than BM-MSCs in reducing neutrophil infiltration, but administration of BM-MSCs or AD-MSCs was more effective at reducing inflammatory cytokines and improving lung function than LR-MSCs. Li *et al*[115] reported that downregulation of Hippo signaling through silencing of large tumor suppressor kinase 1 in murine BM-MSCs significantly increased their differentiation into AT-II cells and decreased pulmonary edema and inflammation in ARDS lung tissue.

Few studies have explored the therapeutic role of MSCs during prion infection and found that transplantation of human BM-MSCs intravenously or intrahippocampally improved the survival of prion-infected mice. The transplanted MSCs differentiated into neuronal and glial cells[13]. Migration of human MSCs to the site of prion infection was found to be mediated by CCR3, CCR5, CXCR3, and CXCR4, and blocking these receptors in the MSCs inhibited their migration to the infected site[129]. Furthermore, treatment with MSCs has been found to promote tissue regeneration and reduction of pathogen load in various parasitic infections such as malaria[14], Chagas disease[130,131], schistosomiasis[116,132,133], and leishmaniasis[134]. Thus, MSCs repair pathogen-induced tissue damage by direct differentiation or through the secretion of various mitogens and regulatory factors.

**MSC-derived paracrine factors and EVs**

MSCs secrete bilayered lipid microvesicles (100-1000 nm) and exosomes (30-100 nm) that contain cytokines, microRNAs (miRNAs), chemokines, and AMPs[135-138]. MiRNAs present in MSC-derived exosomes play an important role in mediating therapeutic effects. Exosome-derived miR-27a-3p was found to inhibit NF-κB expression and induce M2 polarization in macrophages[139]. miRNA-146a found in the exosomes of IL1-β primed MSC-induced M2 polarization in macrophages by modulating IRAK1, TRAF6, and IRF5 signaling[140]. Furthermore, microvesicles from IFN-γ-primed MSCs were more efficient than those of naïve MSCs in inducing M2 phenotype and phagocytosis in macrophages[141]. EVs secreted by MSCs contain mRNA of KGF[142] and Ang1[68], which mediate anti-inflammatory effects on LPS-induced ALI mice models. In an *E. coli-*induced pneumonia mouse model, MSC-derived EVs upregulated the BALF levels of leukotriene B4 (LTB4), a lipid mediator that acts as a chemoattractant for T cells, neutrophils, macrophages, and other immune cells, thereby facilitating pathogen elimination[143,144]. miRNA-145 present in EVs of MSCs was found to suppress the expression of multidrug resistant protein 1, leading to increased LTB4 production, which enhanced microbial clearance[143]. miR-100 found in WJ-MSC-derived EVs enhanced autophagy through mTOR downregulation and improved the survival of alveolar epithelial cells[110] (Figure 4). Treatment with MSC-derived EVs upregulated KGF, PGE2, IL-10 levels and reduced lung inflammation and endothelial permeability in a pre-clinical model of ischemia reperfusion-induced lung injury[145]. Wang *et al*[146] reported that HGF present in EVs and conditioned media (CM) of BM-MSCs reduced the permeability of endothelial barrier by modulating VE-cadherin and occludin expression. Khatri *et al*[147] reported that swine BM-MSCs and the EVs derived from them have similar surface marker expression, and treatment with EVs had similar anti-inflammatory effects as that of MSCs themselves in pig ALI.

UC-MSC-derived EVs inhibited viral replication of hepatitis C virus (HCV) in a pre-clinical disease model, and the anti-viral effect was found to be mediated by miRNAs let-7f, miR-145, miR-199a, and miR-221[148]. Human BM-MSC-derived exosomes were found to induce autophagy but inhibit D-GalN/LP-induced apoptosis of hepatocytes[149] as well as coxsackievirus B3-induced myocarditis[150]. Treatment with MSC-derived exosomes modulated AMPK/mTOR signaling in human cardiomyocytes *in vitro* and promoted their survival[150].

CM derived from MSCs cultured in xenofreeconditions has been hypothesized as a reasonable approach to cell-free therapy. The CM was found to be rich in exosomes, EVs, and several paracrine factors[151]. In an LPS-induced ALI mouse model, Su *et al*[152] reported that mice injected intravenously with the CM of MSCs showed reduced neutrophil infiltration and accumulation. MSCs-CM was also shown to induce apoptosis in neutrophils both *in vitro* and *in vivo* by inhibiting NF-κB signaling*.* BALF of MSC-CM-treated mice had reduced levels of anti-apoptotic proteins such as Bcl-xL and Mcl-1[152]. Treatment with MSC-derived CM reduced TNF-α, IL-6 levels and increased IL-10 secretion by macrophages stimulated with TLR ligands or live *S. pneumoniae*[153]. However, Hayes *et al*[154] showed that administration of MSCs was significantly more effective in improving ventilation-induced lung injury than treatment with MSCs-CM alone. In an *ex-vivo* perfusion lung injury model of pneumonia, Park *et al*[155] found that EVs derived from human BM-MSCs treated with TLR3 ligand, poly (I:C) significantly reduced the bacterial load, inflammation, and protein permeability compared to EVs derived from naïve MSCs. CM of murine BM-MSCs was found to exhibit pathogen-related differences in their therapeutic effect, where treatment with MSCs-CM inhibited herpes virus replication but not dengue or enterovirus[148].

**Genetic modifications and priming of MSCs**

Several studies have reported that genetic modifications of MSCs improved their efficacy and therapeutic potential (Table 1). Martínez-González *et al*[156] found that intravenous injection of MSCs overexpressing sST2, a soluble decoy receptor for IL-33, was highly effective at reducing inflammation and preserving the lung architecture compared to naïve MSCs in a murine ALI model. IL-33/IL-1 receptor-like (ST2) signaling 'alarms' and activates the immune cells upon damage of epithelial or endothelial cells[157]. Similarly, administration of MSCs overexpressing Ang1 or HO-1 reduced vascular endothelial permeability and inflammatory cells in the lungs of LPS-induced ALI animal models[78,158,159]. Intratracheal administration of TGF-β1 overexpressing MSCs increased Treg cells but decreased Th17 cells in the lungs of LPS-induced ARDS mice. MSCs expressing TGF-β1 induced occludin protein expression and improved vascular permeability[160]. In an *E. coli-*induced pneumosepsis experimental model, injection of human UC-MSCs that overexpressed IL-10 were highly effective in reducing the percentage of alveolar neutrophils and macrophages and also increased the phagocytic function of macrophages compared to naïve MSCs, leading to significantly reduced bacterial counts[75]. Murine BM-MSCs overexpressing either developmental endothelial locus-1 or FGF2 were found to attenuate lung injury and infiltration of immune cells and reduced TNF-α levels compared to control MSCs in an LPS-induced ALI mouse model[161,162]. HGF overexpressing MSCs reduced apoptosis and cell permeability in LPS-treated pulmonary endothelial cells by upregulating occludin *via* the mTOR/STAT3 signaling pathway[163]. BM-MSCs overexpressing β-catenin, Wnt5a receptor, ROR2, or p130/E2F4 showed higher retention in the lungs and differentiation into AT II cells compared to control MSCs, leading to significant improvement in lung tissue structure in LPS-induced ARDS mouse models[114,121,164]. Angiotensin-converting enzyme (ACE) and its homolog ACE2 are cell membrane-linked enzymes that have important catalytic functions in the rennin-angiotensin system. Although ACE, angiotensin II type 1a receptor, and angiotensin II are involved in the progression of ARDS by increasing edema and disturbing lung function, its homolog ACE2 and angiotensin II type 2 receptor play a protective role during sepsis-induced lung injury[165]. He *et al*[166] reported that treatment with MSCs expressing ACE2 led to a significant reduction in neutrophil counts and inflammatory cytokines, IL-6, and TNF-α levels in the lungs of LPS-induced ARDS mice compared to the control BM-MSC-treated group. However, ACE2 was found to be the functional receptor for coronaviruses including severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV-1), and SARS-CoV-2 and has been implicated in the progression of SARS-induced ARDS[167,168]. Thus, ACE2 overexpressing MSCs might not be a suitable option for the treatment of SARS-induced ARDS.

Migration of MSCs to the site of infection and injury is required for MSCs to exhibit their therapeutic effects. Overexpression of CXCR4, a receptor for stromal cell-derived factor-1α (SDF-1) in MSCs, improved their migration potential to the injured lungs, which in turn contributed significantly to controlling the tissue damage compared to control MSCs[169]. Because PGE2 levels increase significantly during lung injury, Han *et al*[170] overexpressed the E-prostanoid receptor (EP-2), a receptor for PGE2, in MSCs to improve their homing to the injured lung. EP-2 expressing MSCs showed significantly high migration to the injured lung and repaired the damaged tissue in the ARDS model[[171](#_ENREF_172" \o "Han, 2016 #291)]. In an oral mucositis rat model, Shen *et al*[172] found that overexpression of CXCR2 facilitated the migration of MSCs to the infected site. CXCR2 is a receptor for NAP2, secreted by NK cells at the injury site, and can act as a chemoattractant for MSCs expressing CXCR2[171].

MSCs modify their paracrine secretome depending on the environmental cues. Pre-conditioning MSCs with different environmental cues was found to alter their immunomodulation and differentiation abilities. MSCs pre-conditioned with the serum of ARDS mice or inflammatory cytokines had high expression of IL-10, IL-6, and IL1RA but significantly lower expression of inflammatory cytokines[140,173,174]. Similarly, stimulation of MSCs with pro-inflammatory cytokines TNF-α and IL1-β induced the expression of HGF, FGF2, heparin-binding EGF-like growth factor that contributed to the healing of airway epithelial cells *in vitro* by modulating ERK1/2 phosphorylation *via* EGFR activation[66]. Similarly, MSCs primed with IL1-β were more effective at reducing TNF-α and IL-6 levels and increasing IL-10 levels in serum of ARDS mice[140]. During co-culture of human BM-MSCs and macrophages, TNF-α secreted by activated M1 macrophages induced MSCs into the immunosuppressive phenotype. This effect was amplified by IL-10 produced by M2 macrophages, which further increased PGE2 secretion by MSCs[175]. Treatment of MSCs with either IFN-γ or TNF-α increased PGE2 expression, but IDO and PD-L1 levels increased only in IFN-γ-treated MSCs[69], which suggests that the composition of the inflammatory milieu alters the function of MSCs and their anti-inflammatory potential. Pre-treatment of UC-MSCs with TGF-β1 prior to transplantation improved their long-term survival in the lungs[176]. Long-chain fatty acids such as eicosapentaenoic acid treatment improved the therapeutic effects of MSCs, which led to a reduction in lung injury and increased secretion of inflammation resolving factors such as resolvin D1, IL-10, TGF-β, and PGE2 in a CLP-induced sepsis model[177]. Exposure to IFN-γ or TLR3 ligand poly (I:C) increased HLA-I expression in MSCs, which protected the cells from killing by NK cells[56,178]. Furthermore, murine BM-MSCs pre-conditioned with TLR3 ligand poly (A:U) were more efficient than naïve MSCs in eliminating *M. bovis* in an experimental model[85]. TLR4 activation in LPS-stimulated MSCs expedited wound healing by promoting neutrophil migration and NETosis at the site of infection[79]. Extracellular vesicles from IFN-γ-primed MSCs significantly increased the phagocytotic ability of THP1 monocytic cells *in vitro* and improved the lung histopathology and survival of *E. coli*-induced ARDS mice[141].

In a pre-clinical model, Liu *et al*[117] reported that transplantation of MSCs expressing short hairpin RNA against hepatitis viral proteins (HBV S and HBV X) significantly reduced HBV antigens in the liver and serum. Masalova *et al*[179] tested the efficacy of utilizing MSCs as an immunization agent against HCV and found that murine BM-MSCs expressing five non-structural HCV proteins induced significantly higher proliferation of lymphocytes, IFN-γ secretion, and IgG2a levels compared to naked DNA immunizations suggesting the feasibility of utilizing modified MSCs as vaccine agents. Hypoxic pre-conditioning also improves the migration, survival, and anti-inflammatory properties of MSCs[174,180,181]. MSCs cultured under hypoxic conditions (1% O2) had high expression of SDF-1α receptors CXCR4 and CXCR7, which promoted their migration to the site of infection[180]. Although both short- and long-term hypoxia increased metabolic activity of BM-MSCs compared to normoxic conditions, short-term hypoxia was superior to long-term hypoxia in augmenting the therapeutic characteristic of MSCs. Hypoxic treatment altered the secretome of porcine BM-MSCs and human BM-MSCs differently, indicating species-specific variations in MSCs characteristics[181]. Pre-conditioning of MSCs from human bone marrow and adipose tissue with hypoxia (2% O2) significantly inhibited the differentiation potential but increased the metabolic activity of MSCs. Treatment with cytokine mix consisting of IL-1β, TNF-α, and IFN-γ increased the secretion of anti-inflammatory cytokines such as IL1RA and IL-10 as well as thrombogenic tissue factor in both AD-MSCs and BM-MSCs[174]. Similarly, subpopulations of MSCs selected based on the expression of specific cell surface markers showed a higher therapeutic effect compared to the bulk population. Masterson *et al*[7] found that intravenous administration of a homogenous population of syndecan2 (CD362)-positive BM-MSCs significantly improved the lung function and reduced inflammatory response during lung injury induced by *E. coli* compared to CD362-negative BM-MSCs. Similarly*,* PDGFR+Sca1+TER119- (PαS) BM-MSCs with high CFU-F ability were reported to reduce bacterial load, ameliorate inflammation, and increase survival in mice model of ALI induced by *Klebsiella* *pneumonia*[6]; albeit, the results were not compared with the effects seen with bulk MSCs population.

The route of administration of MSCs can also modify the therapeutic outcome. Danchuk *et al*[20] found that, whereas administration of human BM-MSCs through intravenous, oropharyngeal, or intraperitoneal routes reduced the pulmonary inflammation to a similar extent in an ALI mouse model, MSCs were not detected in the lung after intraperitoneal injection during their analysis period. Interestingly, intravenous administration of murine BM-MSCs was found to be beneficial in ameliorating ALI caused by intratracheal rather than intravenous injection of LPS. Extrapulmonary organ damage induced by intravenous LPS injection reduced the migration and retention of MSCs in the lungs and accounted for the difference in therapeutic effects observed between these two modes of injury[182]. In a mouse model of prion infection, intravenous or intrahippocampal administration of human BM-MSCs enhanced the survival of infected mice; however, the survival rate was higher in the experimental group where MSCs were transplanted intrahippocampally[13].

**Clinical trials with MSCs**

***Liver injury***

In a clinical trial involving 56 patients with hepatitis B infection, intra-hepatic administration of autologous BM-MSCs along with anti-viral drug Entecavir resulted in a significant reduction of inflammation and improvement in liver function[183]. Similar therapeutic benefits were observed in HBV-induced decompensated liver cirrhosis patients when UC-MSCs were intravenously administrated along with standard therapy[184]; however, UC-MSC administration did not alter the prognosis in HBV infection-related acute-on-chronic liver failure patients[185]. Conversely, prolonged treatment with UC-MSCs for more than 4 wk was found to be effective at improving some but not all liver injury markers in HBV-related liver failure and liver cirrhosis patients[186]. In a clinical trial involving hepatitis C patients with end-stage liver disease, intravenous administration of autologous BM-MSCs was found to be well tolerated and effective at reducing liver injury markers and fibrosis[187].

***Lung injury***

Respiratory tract infections claim more than 1.5 million lives annually, and with epidemic and pandemic outbreaks, the number of deaths and disabilities can be devastatingly high (SARS outbreak in 2002, H1N1 flu in 2009, Middle East respiratory syndrome coronavirus outbreak in 2012, and COVID-19 outbreak in 2020)[188]. Based on the successful outcomes observed in pre-clinical models of bacterial pneumonia and respiratory infection, the potential benefits of MSC administration were explored for treating infection-associated lung injury. Avian influenza viruses associated with high mortalities in poultry pose a risk to cross the interspecies barrier to give rise to influenza strains that can cause pandemics[189,190]. In a clinical trial involving 17 patients infected with H7N9, treatment with allogeneic menstrual blood-derived MSCs significantly reduced the death rate (54.5% in control *vs* 17.6% in MSCs treated) and improved lung function without any adverse side effects over a follow-up period of 5 years[191]. In a case study, intra-atrial injection of allogeneic BM-MSCs facilitated resolution of ARDS in a deteriorating critically ill 58-year-old patient with H1N1 infection[192].

***COVID-19***

MSCs are immune to infection by SARS-CoV-2 as they lack the expression of ACE2 and serine protease TMRSS2, which are essential for SARS-CoV-2 infection[193]. In a clinical trial of a critically ill 54-year-old man with COVID-19 pneumonia, administration of allogeneic WJ-MSCs showed no side effects, improved lung function, and diminished the infection by the 6th d of transplantation[194]. In another clinical trial involving seven COVID-19 patients with severe pneumonia, MSC treatment was found to be safe and effective at reducing inflammation[193]. MSC transplantation was reported to act synergistically with convalescent plasma therapy and improve lung injury in another critically ill 66-year-old COVID-19 patient[195]. Severely ill COVID-19 patients are at a risk of thromboembolism that can lead to multiorgan failure. The rationale for using MSCs in treating COVID-19 was discussed in several reports[196-198]; however, treatment of COVID-19 patients with MSCs requires further analysis considering certain aspects of COVID-19-related pathology. Since MSCs often have a high expression of procoagulant tissue factor CD142, intravenous administration of MSCs can be detrimental in patients at risk of systemic coagulation[199], and intratracheal or intramuscular administration can obviate this risk. In another clinical trial of 25 COVID-19 patients receiving MSCs transplantation once, twice, or thrice at intervals of 5 d, three patients developed complications such as liver failure, heart failure, and allergic reactions[200].

**Challenges in utilizing MSCs**

Although MSCs have potent anti-inflammatory and multipotent differentiation properties, some studies have reported that MSCs can act as “safe harbors” for some bacterial and viral pathogens and help them evade the immune response and therapeutic drugs. An *in vitro* study by Naik *et al*[201] reported that BM-MCs could be infected by both virulent (*M. tuberculosis*) and avirulent (*M. bovis, M. smegmatis*) mycobacteria. However, MSCs effectively eliminated the intracellular avirulent species but not the virulent mycobacteria. *M. bovis* elimination was mediated by activation of TLR2/4 pathway. In contrast, intracellular survival of *M. tuberculosis* was facilitated by bacteria-induced downregulation of CRAMP, an AMP expressed in BM-MSCs[201]. Intracellular *M. tuberculosis* in MSCs were drug-resistant, attributed to the expression of drug-efflux pumps ABCC1 and ABCG2, and immune protected, due to PGE2 secretion by MSCs[202]. Lopes *et al*[203] found that CD271+Sca1+ BM-MSCs served as a niche for *Leishmania infantum in vivo*, which protected the parasite from anti-parasite drugs, possibly through active drug pump ABCG2 expressed by MSCs.

Qiao *et al*[204]and Soland *et al*[205] reported that human MSCs were fully permissive to human cytomegalovirus infection, and the highest infection rate was observed in lung perivascular MSCs, suggesting that MSCs in different organs might act as a viral reservoir in humans. Further, Meisel *et al*[206] found that MSCs infected with CMV lose their immunosuppressive and antimicrobial properties, and Sundin *et al*[207] found that parvovirus B19 persisted in BM-MSCs even after several years of infection. Human placenta-derived MSCs were found to be permissible to infection with HSV such as HSV1 and HSV2, and fetal membrane-derived MSCs are susceptible to infection with Varicella Zoster Virus[208]. Human BM-MSCs were found to be susceptible to HBV infection[209], and Wang *et al*[210] reported that while BM-MSCs from patients with chronic HBV infection had defective differentiation potential, AD-MSCs were not permissible to HBV infection and differentiated effectively into functional hepatocyte-like cells. Therefore, AD-MSCs might be a better therapeutic option than BM-MSCs in patients with HBV infection. Similarly, avian influenza virus H5N1 was also reported to infect and induce cell death in human BM-MSCs and cord blood-derived MSCs[211]. MSCs are also susceptible to HIV infection since they express receptors and co-receptors for HIV-1. Cotter *et al*[212] reported that HIV-1 infection alters the differentiation potential of MSCs, and MSCs exposed to sera from patients with high viral load showed proadipogenic phenotype. BM-MSCs from HIV transgenic mice showed a reduction in proliferation and therapeutic effects on an acute kidney injury model compared to normal BM-MSCs[213]. Cervenakova *et al*[214] reported that BM-MSCs from mice infected with prions were able to propagate TSE agents or prions when transplanted into healthy animals. Thus, due considerations on the susceptibility of MSCs to various infectious agents should be given while utilizing MSCs for therapy.

Although several studies have reported that MSCs are non-immunogenic due to lack of MHC II and the co-stimulatory molecules CD40, CD80, or CD86 and that the allogenic MSCs are well tolerated[191,192], some studies have found that allogenic MSCs elicit an immune response in the recipients leading to transplantation failure[215-217]. Furthermore, MSCs from different tissue sources have varied differentiation ability and secrete a unique set of immunomodulatory factors which might influence the clinical outcome, and these source-specific differences are reviewed in detail elsewhere[198,218]. Further studies are required to understand the immune response elicited by allogeneic MSCs transplantation as well as the diverse effects of utilizing MSCs isolated from different tissue sources. An important point to consider is that several pre-clinical studies were performed in animal models with non-human MSCs or human MSCs from various tissue sources. The non-human inflammatory milieu might not exactly resemble the disease conditions seen in humans, and thus additional precautions should be taken while interpreting the potential benefits of utilizing MSCs for the treatment of infectious diseases.

**CONCLUSION**

Exaggerated immune response and inflammation during infections cause tissue damage, which is one of the major reasons for infectious disease-induced mortality. However, treatment with MSCs was reported to provide therapeutic benefits by reducing inflammation, pathogen load, and tissue damage in several disease models. By expediting pathogen clearance through secretion of AMPs and direct phagocytosis and by reducing inflammation through secretion of several anti-inflammatory cytokines, MSCs combat tissue damage at the site of infection. MSCs play an important role in tissue regeneration by secreting various mitogens as well as differentiating into cells of the target tissue. During ARDS, secretion of LXA4, Ang1, HGF, and VEGF by MSCs upregulate the expression of ion channel and tight junction proteins and thus restore AFC and reduce endothelial permeability. MSC-derived EVs contain several therapeutically beneficial cytokines, miRNAs, and treatment with MSC-EVs showed promising results in clinical trials involving patients with liver injuries and severe COVID-19 pneumonia. However, caution should be exercised in utilizing MSCs for treatment as they can harbor harmful pathogens and might cause unfavorable outcomes in patients with pre-existing conditions.

**REFERENCES**

1 **Dominici M**, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]

2 **Mawrie D**, Bhattacharjee K, Sharma A, Sharma R, Bhattacharyya J, Bhattacharjee H, Deori N, Kumar A, Jaganathan BG. Human orbital adipose tissue-derived mesenchymal stem cells possess neuroectodermal differentiation and repair ability. *Cell Tissue Res* 2019; **378**: 531-542 [PMID: 31377878 DOI: 10.1007/s00441-019-03072-0]

3 **Mawrie D**, Kumar A, Magdalene D, Bhattacharyya J, Jaganathan BG. Mesenchymal Stem Cells from Human Extra Ocular Muscle Harbor Neuroectodermal Differentiation Potential. *PLoS One* 2016; **11**: e0156697 [PMID: 27248788 DOI: 10.1371/journal.pone.0156697]

4 **Tetro JA**. From hidden outbreaks to epidemic emergencies: the threat associated with neglecting emerging pathogens. *Microbes Infect* 2019; **21**: 4-9 [PMID: 29959095 DOI: 10.1016/j.micinf.2018.06.004]

5 **Mushahary D**, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. *Cytometry A* 2018; **93**: 19-31 [PMID: 29072818 DOI: 10.1002/cyto.a.23242]

6 **Hackstein H**, Lippitsch A, Krug P, Schevtschenko I, Kranz S, Hecker M, Dietert K, Gruber AD, Bein G, Brendel C, Baal N. Prospectively defined murine mesenchymal stem cells inhibit Klebsiella pneumoniae-induced acute lung injury and improve pneumonia survival. *Respir Res* 2015; **16**: 123 [PMID: 26438075 DOI: 10.1186/s12931-015-0288-1]

7 **Masterson C**, Devaney J, Horie S, O'Flynn L, Deedigan L, Elliman S, Barry F, O'Brien T, O'Toole D, Laffey JG. Syndecan-2-positive, Bone Marrow-derived Human Mesenchymal Stromal Cells Attenuate Bacterial-induced Acute Lung Injury and Enhance Resolution of Ventilator-induced Lung Injury in Rats. *Anesthesiology* 2018; **129**: 502-516 [PMID: 29979191 DOI: 10.1097/ALN.0000000000002327]

8 **Grau-Vorster M**, Laitinen A, Nystedt J, Vives J. HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study. *Stem Cell Res Ther* 2019; **10**: 164 [PMID: 31196185 DOI: 10.1186/s13287-019-1279-9]

9 **Grau-Vorster M**, Rodríguez L, Torrents-Zapata S, Vivas D, Codinach M, Blanco M, Oliver-Vila I, García-López J, Vives J. Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow-derived multipotent mesenchymal stromal cell expansion cultures. *Cytotherapy* 2019; **21**: 32-40 [PMID: 30447901 DOI: 10.1016/j.jcyt.2018.09.009]

10 **Polchert D**, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft *vs* host disease. *Eur J Immunol* 2008; **38**: 1745-1755 [PMID: 18493986 DOI: 10.1002/eji.200738129]

11 **Adak S**, Magdalene D, Deshmukh S, Das D, Jaganathan BG. A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases. *Stem Cell Rev Rep* 2021 [PMID: 33410097 DOI: 10.1007/s12015-020-10090-x]

12 **Liu HM**, Liu YT, Zhang J, Ma LJ. Bone marrow mesenchymal stem cells ameliorate lung injury through anti-inflammatory and antibacterial effect in COPD mice. *J Huazhong Univ Sci Technolog Med Sci* 2017; **37**: 496-504 [PMID: 28786060 DOI: 10.1007/s11596-017-1763-3]

13 **Song CH**, Honmou O, Ohsawa N, Nakamura K, Hamada H, Furuoka H, Hasebe R, Horiuchi M. Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions. *J Virol* 2009; **83**: 5918-5927 [PMID: 19297502 DOI: 10.1128/JVI.00165-09]

14 **Thakur RS**, Tousif S, Awasthi V, Sanyal A, Atul PK, Punia P, Das J. Mesenchymal stem cells play an important role in host protective immune responses against malaria by modulating regulatory T cells. *Eur J Immunol* 2013; **43**: 2070-2077 [PMID: 23670483 DOI: 10.1002/eji.201242882]

15 **Tsuchiya A**, Takeuchi S, Iwasawa T, Kumagai M, Sato T, Motegi S, Ishii Y, Koseki Y, Tomiyoshi K, Natsui K, Takeda N, Yoshida Y, Yamazaki F, Kojima Y, Watanabe Y, Kimura N, Tominaga K, Kamimura H, Takamura M, Terai S. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. *Inflamm Regen* 2020; **40**: 14 [PMID: 32582401 DOI: 10.1186/s41232-020-00121-y]

16 **Van Linthout S**, Savvatis K, Miteva K, Peng J, Ringe J, Warstat K, Schmidt-Lucke C, Sittinger M, Schultheiss HP, Tschöpe C. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. *Eur Heart J* 2011; **32**: 2168-2178 [PMID: 21183501 DOI: 10.1093/eurheartj/ehq467]

17 **Yudintceva NM**, Bogolyubova IO, Muraviov AN, Sheykhov MG, Vinogradova TI, Sokolovich EG, Samusenko IA, Shevtsov MA. Application of the allogenic mesenchymal stem cells in the therapy of the bladder tuberculosis. *J Tissue Eng Regen Med* 2018; **12**: e1580-e1593 [PMID: 28990734 DOI: 10.1002/term.2583]

18 **Fu X**, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal Stem Cell Migration and Tissue Repair. *Cells* 2019; **8** [PMID: 31357692 DOI: 10.3390/cells8080784]

19 **Tse WT**, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation* 2003; **75**: 389-397 [PMID: 12589164 DOI: 10.1097/01.TP.0000045055.63901.A9]

20 **Danchuk S**, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW, Lasky JA, Bunnell BA, Welsh DA, Prockop DJ, Sullivan DE. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice *via* secretion of tumor necrosis factor-α-induced protein 6. *Stem Cell Res Ther* 2011; **2**: 27 [PMID: 21569482 DOI: 10.1186/scrt68]

21 **Dushianthan A**, Grocott MP, Postle AD, Cusack R. Acute respiratory distress syndrome and acute lung injury. *Postgrad Med J* 2011; **87**: 612-622 [PMID: 21642654 DOI: 10.1136/pgmj.2011.118398]

22 **Zhao W**, Li JJ, Cao DY, Li X, Zhang LY, He Y, Yue SQ, Wang DS, Dou KF. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. *World J Gastroenterol* 2012; **18**: 1048-1058 [PMID: 22416179 DOI: 10.3748/wjg.v18.i10.1048]

23 **Dürr UH**, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim Biophys Acta* 2006; **1758**: 1408-1425 [PMID: 16716248 DOI: 10.1016/j.bbamem.2006.03.030]

24 **Krasnodembskaya A**, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* 2010; **28**: 2229-2238 [PMID: 20945332 DOI: 10.1002/stem.544]

25 **Duplantier AJ**, van Hoek ML. The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds. *Front Immunol* 2013; **4**: 143 [PMID: 23840194 DOI: 10.3389/fimmu.2013.00143]

26 **Sutton MT**, Fletcher D, Ghosh SK, Weinberg A, van Heeckeren R, Kaur S, Sadeghi Z, Hijaz A, Reese J, Lazarus HM, Lennon DP, Caplan AI, Bonfield TL. Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment. *Stem Cells Int* 2016; **2016**: 5303048 [PMID: 26925108 DOI: 10.1155/2016/5303048]

27 **Johnson EE**, Wessling-Resnick M. Iron metabolism and the innate immune response to infection. *Microbes Infect* 2012; **14**: 207-216 [PMID: 22033148 DOI: 10.1016/j.micinf.2011.10.001]

28 **Gupta N**, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. *Thorax* 2012; **67**: 533-539 [PMID: 22250097 DOI: 10.1136/thoraxjnl-2011-201176]

29 **Xiao X**, Yeoh BS, Vijay-Kumar M. Lipocalin 2: An Emerging Player in Iron Homeostasis and Inflammation. *Annu Rev Nutr* 2017; **37**: 103-130 [PMID: 28628361 DOI: 10.1146/annurev-nutr-071816-064559]

30 **Sung DK**, Chang YS, Sung SI, Yoo HS, Ahn SY, Park WS. Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin- 2 *via* toll- like receptor 4 signalling. *Cell Microbiol* 2016; **18**: 424-436 [PMID: 26350435 DOI: 10.1111/cmi.12522]

31 **MacKenzie CR**, Heseler K, Müller A, Däubener W. Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion *vs* production of toxic kynurenines. *Curr Drug Metab* 2007; **8**: 237-244 [PMID: 17430112 DOI: 10.2174/138920007780362518]

32 **Khan A**, Mann L, Papanna R, Lyu MA, Singh CR, Olson S, Eissa NT, Cirillo J, Das G, Hunter RL, Jagannath C. Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. *Sci Rep* 2017; **7**: 15010 [PMID: 29118429 DOI: 10.1038/s41598-017-15290-z]

33 **Rodrigues ES**, de Macedo MD, Orellana MD, Takayanagui OM, Palma PVB, Pinto MT, de Oliveira GLV, Malmegrim KCR, Slavov SN, Covas DT, Kashima S. Short Communication: Human Bone Marrow Stromal Cells Exhibit Immunosuppressive Effects on Human T Lymphotropic Virus Type 1 T Lymphocyte from Infected Individuals. *AIDS Res Hum Retroviruses* 2019; **35**: 164-168 [PMID: 30351194 DOI: 10.1089/AID.2018.0066]

34 **Klimova RR**, Momotyuk ЕD, Demidova NA, Yarigina EI, Kushch AA. [Mesenchymal stem cells enhance immune response and protect mice against lethal herpes viral infection.] *Vopr Virusol* 2018; **63**: 261-267 [PMID: 30641021 DOI: 10.18821/0507-4088-2018-63-6-261-267]

35 **Abraham E**, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2000; **279**: L1137-L1145 [PMID: 11076804 DOI: 10.1152/ajplung.2000.279.6.L1137]

36 **Li T**, Zhang Z, Li X, Dong G, Zhang M, Xu Z, Yang J. Neutrophil Extracellular Traps: Signaling Properties and Disease Relevance. *Mediators Inflamm* 2020; **2020**: 9254087 [PMID: 32774152 DOI: 10.1155/2020/9254087]

37 **Liu S**, Su X, Pan P, Zhang L, Hu Y, Tan H, Wu D, Liu B, Li H, Li H, Li Y, Dai M, Li Y, Hu C, Tsung A. Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury. *Sci Rep* 2016; **6**: 37252 [PMID: 27849031 DOI: 10.1038/srep37252]

38 **Leppkes M**, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, Stürzl M, Staats L, Mahajan A, Schauer C, Kremer AN, Völkl S, Amann K, Evert K, Falkeis C, Wehrfritz A, Rieker RJ, Hartmann A, Kremer AE, Neurath MF, Muñoz LE, Schett G, Herrmann M. Vascular occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine* 2020; **58**: 102925 [PMID: 32745993 DOI: 10.1016/j.ebiom.2020.102925]

39 **Dyer DP**, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AE, Day AJ, Milner CM. TSG-6 inhibits neutrophil migration *via* direct interaction with the chemokine CXCL8. *J Immunol* 2014; **192**: 2177-2185 [PMID: 24501198 DOI: 10.4049/jimmunol.1300194]

40 **Jiang D**, Muschhammer J, Qi Y, Kügler A, de Vries JC, Saffarzadeh M, Sindrilaru A, Beken SV, Wlaschek M, Kluth MA, Ganss C, Frank NY, Frank MH, Preissner KT, Scharffetter-Kochanek K. Suppression of Neutrophil-Mediated Tissue Damage-A Novel Skill of Mesenchymal Stem Cells. *Stem Cells* 2016; **34**: 2393-2406 [PMID: 27299700 DOI: 10.1002/stem.2417]

41 **Rabani R**, Volchuk A, Jerkic M, Ormesher L, Garces-Ramirez L, Canton J, Masterson C, Gagnon S, Tatham KC, Marshall J, Grinstein S, Laffey JG, Szaszi K, Curley GF. Mesenchymal stem cells enhance NOX2-dependent reactive oxygen species production and bacterial killing in macrophages during sepsis. *Eur Respir J* 2018; **51** [PMID: 29519920 DOI: 10.1183/13993003.02021-2017]

42 **Orecchioni M**, Ghosheh Y, Pramod AB, Ley K. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages. *Front Immunol* 2019; **10**: 1084 [PMID: 31178859 DOI: 10.3389/fimmu.2019.01084]

43 **Luz-Crawford P**, Djouad F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, Jorgensen C, Noël D. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation. *Stem Cells* 2016; **34**: 483-492 [PMID: 26661518 DOI: 10.1002/stem.2254]

44 **Kwon JH**, Kim M, Bae YK, Kim GH, Choi SJ, Oh W, Um S, Jin HJ. Decorin Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induces Macrophage Polarization *via* CD44 to Repair Hyperoxic Lung Injury. *Int J Mol Sci* 2019; **20** [PMID: 31569732 DOI: 10.3390/ijms20194815]

45 **Lv H**, Liu Q, Sun Y, Yi X, Wei X, Liu W, Zhang Q, Yi H, Chen G. Mesenchymal stromal cells ameliorate acute lung injury induced by LPS mainly through stanniocalcin-2 mediating macrophage polarization. *Ann Transl Med* 2020; **8**: 334 [PMID: 32355778 DOI: 10.21037/atm.2020.02.105]

46 **Chen X**, Yang B, Tian J, Hong H, Du Y, Li K, Li X, Wang N, Yu X, Wei X. Dental Follicle Stem Cells Ameliorate Lipopolysaccharide-Induced Inflammation by Secreting TGF-β3 and TSP-1 to Elicit Macrophage M2 Polarization. *Cell Physiol Biochem* 2018; **51**: 2290-2308 [PMID: 30537736 DOI: 10.1159/000495873]

47 **Li B**, Zhang H, Zeng M, He W, Li M, Huang X, Deng DY, Wu J. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway. *Cell Biol Int* 2015; **39**: 192-200 [PMID: 25229877 DOI: 10.1002/cbin.10359]

48 **Jackson MV**, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, O'Kane CM, Krasnodembskaya AD. Mitochondrial Transfer *via* Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS. *Stem Cells* 2016; **34**: 2210-2223 [PMID: 27059413 DOI: 10.1002/stem.2372]

49 **Lu Z**, Chang W, Meng S, Xu X, Xie J, Guo F, Yang Y, Qiu H, Liu L. Mesenchymal stem cells induce dendritic cell immune tolerance *via* paracrine hepatocyte growth factor to alleviate acute lung injury. *Stem Cell Res Ther* 2019; **10**: 372 [PMID: 31801626 DOI: 10.1186/s13287-019-1488-2]

50 **Liu W**, Gao Y, Li H, Wang H, Ye M, Jiang G, Chen Y, Liu Y, Kong J, Liu W, Sun M, Hou M, Yu K. Intravenous transplantation of mesenchymal stromal cells has therapeutic effects in a sepsis mouse model through inhibition of septic natural killer cells. *Int J Biochem Cell Biol* 2016; **79**: 93-103 [PMID: 27521657 DOI: 10.1016/j.biocel.2016.08.013]

51 **Milosavljevic N**, Gazdic M, Simovic Markovic B, Arsenijevic A, Nurkovic J, Dolicanin Z, Djonov V, Lukic ML, Volarevic V. Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells. *Liver Transpl* 2017; **23**: 1040-1050 [PMID: 28481005 DOI: 10.1002/lt.24784]

52 **Luz-Crawford P**, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, Noël D, Jorgensen C, Figueroa F, Djouad F, Carrión F. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. *Stem Cell Res Ther* 2013; **4**: 65 [PMID: 23734780 DOI: 10.1186/scrt216]

53 **Cruz FF**, Borg ZD, Goodwin M, Sokocevic D, Wagner D, McKenna DH, Rocco PR, Weiss DJ. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. *Stem Cells Transl Med* 2015; **4**: 615-624 [PMID: 25925837 DOI: 10.5966/sctm.2014-0268]

54 **Davies LC**, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. *Stem Cells* 2017; **35**: 766-776 [PMID: 27671847 DOI: 10.1002/stem.2509]

55 **Najar M**, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. *Immunol Lett* 2012; **146**: 50-56 [PMID: 22575528 DOI: 10.1016/j.imlet.2012.04.017]

56 **Giuliani M**, Bennaceur-Griscelli A, Nanbakhsh A, Oudrhiri N, Chouaib S, Azzarone B, Durrbach A, Lataillade JJ. TLR ligands stimulation protects MSC from NK killing. *Stem Cells* 2014; **32**: 290-300 [PMID: 24123639 DOI: 10.1002/stem.1563]

57 **Gupta N**, Sinha R, Krasnodembskaya A, Xu X, Nizet V, Matthay MA, Griffin JH. The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. *Stem Cells* 2018; **36**: 796-806 [PMID: 29396891 DOI: 10.1002/stem.2796]

58 **de Witte SFH**, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, Shankar AS, O'Flynn L, Elliman SJ, Roy D, Betjes MGH, Newsome PN, Baan CC, Hoogduijn MJ. Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. *Stem Cells* 2018; **36**: 602-615 [PMID: 29341339 DOI: 10.1002/stem.2779]

59 **Gonçalves FDC**, Luk F, Korevaar SS, Bouzid R, Paz AH, López-Iglesias C, Baan CC, Merino A, Hoogduijn MJ. Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes. *Sci Rep* 2017; **7**: 12100 [PMID: 28935974 DOI: 10.1038/s41598-017-12121-z]

60 **Li W**, Chen W, Huang S, Yao G, Tang X, Sun L. Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity *via* recruiting CXCR3+ regulatory T cells. *Clin Transl Immunology* 2020; **9**: e1181 [PMID: 33014369 DOI: 10.1002/cti2.1181]

61 **Lee JW**, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in *ex vivo* human lungs injured with live bacteria. *Am J Respir Crit Care Med* 2013; **187**: 751-760 [PMID: 23292883 DOI: 10.1164/rccm.201206-0990OC]

62 **Miteva K**, Pappritz K, El-Shafeey M, Dong F, Ringe J, Tschöpe C, Van Linthout S. Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3-Induced Myocarditis. *Stem Cells Transl Med* 2017; **6**: 1249-1261 [PMID: 28186704 DOI: 10.1002/sctm.16-0353]

63 **Li Y**, Xu J, Shi W, Chen C, Shao Y, Zhu L, Lu W, Han X. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. *Stem Cell Res Ther* 2016; **7**: 159 [PMID: 27793190 DOI: 10.1186/s13287-016-0395-z]

64 **Loy H**, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, Peiris JSM, Chan MCW. Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury. *J Infect Dis* 2019; **219**: 186-196 [PMID: 30085072 DOI: 10.1093/infdis/jiy478]

65 **Ahmed AR**, Owens RJ, Stubbs CD, Parker AW, Hitchman R, Yadav RB, Dumoux M, Hawes C, Botchway SW. Direct imaging of the recruitment and phosphorylation of S6K1 in the mTORC1 pathway in living cells. *Sci Rep* 2019; **9**: 3408 [PMID: 30833605 DOI: 10.1038/s41598-019-39410-z]

66 **Broekman W**, Amatngalim GD, de Mooij-Eijk Y, Oostendorp J, Roelofs H, Taube C, Stolk J, Hiemstra PS. TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing *in vitro* *via* activation of the epidermal growth factor receptor. *Respir Res* 2016; **17**: 3 [PMID: 26753875 DOI: 10.1186/s12931-015-0316-1]

67 **Liang C**, Jiang E, Yao J, Wang M, Chen S, Zhou Z, Zhai W, Ma Q, Feng S, Han M. Interferon-γ mediates the immunosuppression of bone marrow mesenchymal stem cells on T-lymphocytes in vitro. *Hematology* 2018; **23**: 44-49 [PMID: 28581352 DOI: 10.1080/10245332.2017.1333245]

68 **Tang XD**, Shi L, Monsel A, Li XY, Zhu HL, Zhu YG, Qu JM. Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice Partly Mediated by Ang-1 mRNA. *Stem Cells* 2017; **35**: 1849-1859 [PMID: 28376568 DOI: 10.1002/stem.2619]

69 **English K**, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. *Immunol Lett* 2007; **110**: 91-100 [PMID: 17507101 DOI: 10.1016/j.imlet.2007.04.001]

70 **Fang X**, Abbott J, Cheng L, Colby JK, Lee JW, Levy BD, Matthay MA. Human Mesenchymal Stem (Stromal) Cells Promote the Resolution of Acute Lung Injury in Part through Lipoxin A4. *J Immunol* 2015; **195**: 875-881 [PMID: 26116507 DOI: 10.4049/jimmunol.1500244]

71 **Wang G**, Cao K, Liu K, Xue Y, Roberts AI, Li F, Han Y, Rabson AB, Wang Y, Shi Y. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. *Cell Death Differ* 2018; **25**: 1209-1223 [PMID: 29238069 DOI: 10.1038/s41418-017-0006-2]

72 **Hu S**, Li J, Xu X, Liu A, He H, Xu J, Chen Q, Liu S, Liu L, Qiu H, Yang Y. The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo. *Stem Cell Res Ther* 2016; **7**: 66 [PMID: 27129877 DOI: 10.1186/s13287-016-0320-5]

73 **Prieto CP**, Ortiz MC, Villanueva A, Villarroel C, Edwards SS, Elliott M, Lattus J, Aedo S, Meza D, Lois P, Palma V. Netrin-1 acts as a non-canonical angiogenic factor produced by human Wharton's jelly mesenchymal stem cells (WJ-MSC). *Stem Cell Res Ther* 2017; **8**: 43 [PMID: 28241866 DOI: 10.1186/s13287-017-0494-5]

74 **Jerkic M**, Gagnon S, Rabani R, Ward-Able T, Masterson C, Otulakowski G, Curley GF, Marshall J, Kavanagh BP, Laffey JG. Human Umbilical Cord Mesenchymal Stromal Cells Attenuate Systemic Sepsis in Part by Enhancing Peritoneal Macrophage Bacterial Killing *via* Heme Oxygenase-1 Induction in Rats. *Anesthesiology* 2020; **132**: 140-154 [PMID: 31764154 DOI: 10.1097/ALN.0000000000003018]

75 **Jerkic M**, Masterson C, Ormesher L, Gagnon S, Goyal S, Rabani R, Otulakowski G, Zhang H, Kavanagh BP, Laffey JG. Overexpression of IL-10 Enhances the Efficacy of Human Umbilical-Cord-Derived Mesenchymal Stromal Cells in *E. coli* Pneumosepsis. *J Clin Med* 2019; **8** [PMID: 31200579 DOI: 10.3390/jcm8060847]

76 **Gamble JR**, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent *in vitro* and targets cell junctions. *Circ Res* 2000; **87**: 603-607 [PMID: 11009566 DOI: 10.1161/01.res.87.7.603]

77 **Xu J**, Qu J, Cao L, Sai Y, Chen C, He L, Yu L. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. *J Pathol* 2008; **214**: 472-481 [PMID: 18213733 DOI: 10.1002/path.2302]

78 **Shalaby SM**, El-Shal AS, Abd-Allah SH, Selim AO, Selim SA, Gouda ZA, Abd El Motteleb DM, Zanfaly HE, El-Assar HM, Abdelazim S. Mesenchymal stromal cell injection protects against oxidative stress in Escherichia coli-induced acute lung injury in mice. *Cytotherapy* 2014; **16**: 764-775 [PMID: 24525173 DOI: 10.1016/j.jcyt.2013.12.006]

79 **Munir S**, Basu A, Maity P, Krug L, Haas P, Jiang D, Strauss G, Wlaschek M, Geiger H, Singh K, Scharffetter-Kochanek K. TLR4-dependent shaping of the wound site by MSCs accelerates wound healing. *EMBO Rep* 2020; **21**: e48777 [PMID: 32162777 DOI: 10.15252/embr.201948777]

80 **Shi C**, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, Leiner I, Li MO, Frenette PS, Pamer EG. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. *Immunity* 2011; **34**: 590-601 [PMID: 21458307 DOI: 10.1016/j.immuni.2011.02.016]

81 **Petri RM**, Hackel A, Hahnel K, Dumitru CA, Bruderek K, Flohe SB, Paschen A, Lang S, Brandau S. Activated Tissue-Resident Mesenchymal Stromal Cells Regulate Natural Killer Cell Immune and Tissue-Regenerative Function. *Stem Cell Reports* 2017; **9**: 985-998 [PMID: 28781075 DOI: 10.1016/j.stemcr.2017.06.020]

82 **Mao YX**, Xu JF, Seeley EJ, Tang XD, Xu LL, Zhu YG, Song YL, Qu JM. Adipose Tissue-Derived Mesenchymal Stem Cells Attenuate Pulmonary Infection Caused by Pseudomonas aeruginosa *via* Inhibiting Overproduction of Prostaglandin E2. *Stem Cells* 2015; **33**: 2331-2342 [PMID: 25788456 DOI: 10.1002/stem.1996]

83 **Agard M**, Asakrah S, Morici LA. PGE(2) suppression of innate immunity during mucosal bacterial infection. *Front Cell Infect Microbiol* 2013; **3**: 45 [PMID: 23971009 DOI: 10.3389/fcimb.2013.00045]

84 **Arango JC**, Puerta-Arias JD, Pino-Tamayo PA, Arboleda-Toro D, González Á. Bone marrow-derived mesenchymal stem cells transplantation alters the course of experimental paracoccidioidomycosis by exacerbating the chronic pulmonary inflammatory response. *Med Mycol* 2018; **56**: 884-895 [PMID: 29253200 DOI: 10.1093/mmy/myx128]

85 **Schwartz YS**, Belogorodtsev SN, Filimonov PN, Cherednichenko AG, Pustylnikov SV, Krasnov VA. BCG infection in mice is promoted by naïve mesenchymal stromal cells (MSC) and suppressed by poly(A:U)-conditioned MSC. *Tuberculosis (Edinb)* 2016; **101**: 130-136 [PMID: 27865382 DOI: 10.1016/j.tube.2016.09.005]

86 **Johnson ER**, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. *J Aerosol Med Pulm Drug Deliv* 2010; **23**: 243-252 [PMID: 20073554 DOI: 10.1089/jamp.2009.0775]

87 **Atabai K**, Ishigaki M, Geiser T, Ueki I, Matthay MA, Ware LB. Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. *Am J Physiol Lung Cell Mol Physiol* 2002; **283**: L163-L169 [PMID: 12060573 DOI: 10.1152/ajplung.00396.2001]

88 **Esquivel D**, Mishra R, Soni P, Seetharaman R, Mahmood A, Srivastava A. Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients. *Stem Cell Rev Rep* 2021; **17**: 144-152 [PMID: 32740890 DOI: 10.1007/s12015-020-10017-6]

89 **Knudsen L**, Ochs M. The micromechanics of lung alveoli: structure and function of surfactant and tissue components. *Histochem Cell Biol* 2018; **150**: 661-676 [PMID: 30390118 DOI: 10.1007/s00418-018-1747-9]

90 **Mowery NT**, Terzian WTH, Nelson AC. Acute lung injury. *Curr Probl Surg* 2020; **57**: 100777 [PMID: 32505224 DOI: 10.1016/j.cpsurg.2020.100777]

91 **Wynne BM**, Zou L, Linck V, Hoover RS, Ma HP, Eaton DC. Regulation of Lung Epithelial Sodium Channels by Cytokines and Chemokines. *Front Immunol* 2017; **8**: 766 [PMID: 28791006 DOI: 10.3389/fimmu.2017.00766]

92 **Lee JW**, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the *ex vivo* perfused human lung. *Proc Natl Acad Sci U S A* 2009; **106**: 16357-16362 [PMID: 19721001 DOI: 10.1073/pnas.0907996106]

93 **Li J**, Huang S, Zhang J, Feng C, Gao D, Yao B, Wu X, Fu X. Mesenchymal stem cells ameliorate inflammatory cytokine-induced impairment of AT-II cells through a keratinocyte growth factor-dependent PI3K/Akt/mTOR signaling pathway. *Mol Med Rep* 2016; **13**: 3755-3762 [PMID: 27035760 DOI: 10.3892/mmr.2016.5004]

94 **Fang X**, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. *J Biol Chem* 2010; **285**: 26211-26222 [PMID: 20554518 DOI: 10.1074/jbc.M110.119917]

95 **Yang Y**, Chen QH, Liu AR, Xu XP, Han JB, Qiu HB. Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation *via* the Rac1 pathway. *Stem Cell Res Ther* 2015; **6**: 250 [PMID: 26674641 DOI: 10.1186/s13287-015-0257-0]

96 **Yang Y**, Cheng Y, Lian QQ, Yang L, Qi W, Wu DR, Zheng X, Liu YJ, Li WJ, Jin SW, Smith FG. Contribution of CFTR to alveolar fluid clearance by lipoxin A4 *via* PI3K/Akt pathway in LPS-induced acute lung injury. *Mediators Inflamm* 2013; **2013**: 862628 [PMID: 23766562 DOI: 10.1155/2013/862628]

97 **Wang Q**, Lian QQ, Li R, Ying BY, He Q, Chen F, Zheng X, Yang Y, Wu DR, Zheng SX, Huang CJ, Smith FG, Jin SW. Lipoxin A(4) activates alveolar epithelial sodium channel, Na,K-ATPase, and increases alveolar fluid clearance. *Am J Respir Cell Mol Biol* 2013; **48**: 610-618 [PMID: 23470626 DOI: 10.1165/rcmb.2012-0274OC]

98 **Ba F**, Zhou X, Zhang Y, Wu C, Xu S, Wu L, Li J, Yin Y, Gu X. Lipoxin A4 ameliorates alveolar fluid clearance disturbance in lipopolysaccharide-induced lung injury *via* aquaporin 5 and MAPK signaling pathway. *J Thorac Dis* 2019; **11**: 3599-3608 [PMID: 31559067 DOI: 10.21037/jtd.2019.08.86]

99 **Shi Z**, Ye W, Zhang J, Zhang F, Yu D, Yu H, Chen B, Zhou M, Sun H. LipoxinA4 attenuates acute pancreatitis-associated acute lung injury by regulating AQP-5 and MMP-9 expression, anti-apoptosis and PKC/SSeCKS-mediated F-actin activation. *Mol Immunol* 2018; **103**: 78-88 [PMID: 30219663 DOI: 10.1016/j.molimm.2018.09.003]

100 **Grumbach Y**, Quynh NV, Chiron R, Urbach V. LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells. *Am J Physiol Lung Cell Mol Physiol* 2009; **296**: L101-L108 [PMID: 18849442 DOI: 10.1152/ajplung.00018.2008]

101 **Kellner M**, Noonepalle S, Lu Q, Srivastava A, Zemskov E, Black SM. ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). *Adv Exp Med Biol* 2017; **967**: 105-137 [PMID: 29047084 DOI: 10.1007/978-3-319-63245-2\_8]

102 **Zorov DB**, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol Rev* 2014; **94**: 909-950 [PMID: 24987008 DOI: 10.1152/physrev.00026.2013]

103 **Cheng X**, He S, Yuan J, Miao S, Gao H, Zhang J, Li Y, Peng W, Wu P. Lipoxin A4 attenuates LPS-induced mouse acute lung injury *via* Nrf2-mediated E-cadherin expression in airway epithelial cells. *Free Radic Biol Med* 2016; **93**: 52-66 [PMID: 26845617 DOI: 10.1016/j.freeradbiomed.2016.01.026]

104 **Yang JX**, Li M, Chen XO, Lian QQ, Wang Q, Gao F, Jin SW, Zheng SX. Lipoxin A4 ameliorates lipopolysaccharide-induced lung injury through stimulating epithelial proliferation, reducing epithelial cell apoptosis and inhibits epithelial-mesenchymal transition. *Respir Res* 2019; **20**: 192 [PMID: 31438948 DOI: 10.1186/s12931-019-1158-z]

105 **Cascone I**, Audero E, Giraudo E, Napione L, Maniero F, Philips MR, Collard JG, Serini G, Bussolino F. Tie-2-dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. *Blood* 2003; **102**: 2482-2490 [PMID: 12816861 DOI: 10.1182/blood-2003-03-0670]

106 **Mammoto T**, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, Ingber DE, Sukhatme VP. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. *J Biol Chem* 2007; **282**: 23910-23918 [PMID: 17562701 DOI: 10.1074/jbc.M702169200]

107 **Chen QH**, Liu AR, Qiu HB, Yang Y. Interaction between mesenchymal stem cells and endothelial cells restores endothelial permeability *via* paracrine hepatocyte growth factor in vitro. *Stem Cell Res Ther* 2015; **6**: 44 [PMID: 25888925 DOI: 10.1186/s13287-015-0025-1]

108 **Yang Y**, Hu S, Xu X, Li J, Liu A, Han J, Liu S, Liu L, Qiu H. The Vascular Endothelial Growth Factors-Expressing Character of Mesenchymal Stem Cells Plays a Positive Role in Treatment of Acute Lung Injury In Vivo. *Mediators Inflamm* 2016; **2016**: 2347938 [PMID: 27313398 DOI: 10.1155/2016/2347938]

109 **Hu Y**, Lou J, Mao YY, Lai TW, Liu LY, Zhu C, Zhang C, Liu J, Li YY, Zhang F, Li W, Ying SM, Chen ZH, Shen HH. Activation of MTOR in pulmonary epithelium promotes LPS-induced acute lung injury. *Autophagy* 2016; **12**: 2286-2299 [PMID: 27658023 DOI: 10.1080/15548627.2016.1230584]

110 **Chen WX**, Zhou J, Zhou SS, Zhang YD, Ji TY, Zhang XL, Wang SM, Du T, Ding DG. Microvesicles derived from human Wharton's jelly mesenchymal stem cells enhance autophagy and ameliorate acute lung injury *via* delivery of miR-100. *Stem Cell Res Ther* 2020; **11**: 113 [PMID: 32169098 DOI: 10.1186/s13287-020-01617-7]

111 **Takeda K**, Ning F, Domenico J, Okamoto M, Ashino S, Kim SH, Jeong YY, Shiraishi Y, Terada N, Sutherland ER, Gelfand EW. Activation of p70S6 Kinase-1 in Mesenchymal Stem Cells Is Essential to Lung Tissue Repair. *Stem Cells Transl Med* 2018; **7**: 551-558 [PMID: 29730892 DOI: 10.1002/sctm.17-0200]

112 **Islam MN**, Das SR, Emin MT, Wei M, Sun L, Westphalen K, Rowlands DJ, Quadri SK, Bhattacharya S, Bhattacharya J. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. *Nat Med* 2012; **18**: 759-765 [PMID: 22504485 DOI: 10.1038/nm.2736]

113 **Ahmad T**, Mukherjee S, Pattnaik B, Kumar M, Singh S, Kumar M, Rehman R, Tiwari BK, Jha KA, Barhanpurkar AP, Wani MR, Roy SS, Mabalirajan U, Ghosh B, Agrawal A. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. *EMBO J* 2014; **33**: 994-1010 [PMID: 24431222 DOI: 10.1002/embj.201386030]

114 **Cai SX**, Liu AR, Chen S, He HL, Chen QH, Xu JY, Pan C, Yang Y, Guo FM, Huang YZ, Liu L, Qiu HB. The Orphan Receptor Tyrosine Kinase ROR2 Facilitates MSCs to Repair Lung Injury in ARDS Animal Model. *Cell Transplant* 2016; **25**: 1561-1574 [PMID: 26531175 DOI: 10.3727/096368915X689776]

115 **Li L**, Dong L, Zhang J, Gao F, Hui J, Yan J. Mesenchymal stem cells with downregulated Hippo signaling attenuate lung injury in mice with lipopolysaccharide‑induced acute respiratory distress syndrome. *Int J Mol Med* 2019; **43**: 1241-1252 [PMID: 30628652 DOI: 10.3892/ijmm.2018.4047]

116 **El-Shennawy SF**, Abdel Aaty HE, Radwan NA, Abdel-Hameed DM, Alam-Eldin YH, El-Ashkar AM, Abu-Zahra FA. Therapeutic Potential of Mesenchymal Stem Cells on Early and Late Experimental Hepatic Schistosomiasis Model. *J Parasitol* 2015; **101**: 587-597 [PMID: 26010300 DOI: 10.1645/15-754.1]

117 **Liu D**, Liu L, Wang L, Duan S, Song Y, Qu M, Gao N, Wu J, Zhang H, Wu H, Kong W, Yu B, Yu X. Therapeutic effects of mesenchymal stem cells combined with short hairpin RNA on liver injury induced by hepatitis B virus infection. *Mol Med Rep* 2018; **17**: 1731-1741 [PMID: 29257255 DOI: 10.3892/mmr.2017.8096]

118 **Zhang GZ**, Sun HC, Zheng LB, Guo JB, Zhang XL. *In vivo* hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis. *World J Gastroenterol* 2017; **23**: 8152-8168 [PMID: 29290652 DOI: 10.3748/wjg.v23.i46.8152]

119 **Zhou Y**, Chen Y, Wang S, Qin F, Wang L. MSCs helped reduce scarring in the cornea after fungal infection when combined with anti-fungal treatment. *BMC Ophthalmol* 2019; **19**: 226 [PMID: 31727008 DOI: 10.1186/s12886-019-1235-6]

120 **Itaba N**, Kono Y, Watanabe K, Yokobata T, Oka H, Osaki M, Kakuta H, Morimoto M, Shiota G. Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets. *Sci Rep* 2019; **9**: 6841 [PMID: 31048740 DOI: 10.1038/s41598-019-43298-0]

121 **Cai SX**, Liu AR, Chen S, He HL, Chen QH, Xu JY, Pan C, Yang Y, Guo FM, Huang YZ, Liu L, Qiu HB. Activation of Wnt/β-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice. *Stem Cell Res Ther* 2015; **6**: 65 [PMID: 25889393 DOI: 10.1186/s13287-015-0060-y]

122 **Liu A**, Chen S, Cai S, Dong L, Liu L, Yang Y, Guo F, Lu X, He H, Chen Q, Hu S, Qiu H. Wnt5a through noncanonical Wnt/JNK or Wnt/PKC signaling contributes to the differentiation of mesenchymal stem cells into type II alveolar epithelial cells in vitro. *PLoS One* 2014; **9**: e90229 [PMID: 24658098 DOI: 10.1371/journal.pone.0090229]

123 **Liu AR**, Liu L, Chen S, Yang Y, Zhao HJ, Liu L, Guo FM, Lu XM, Qiu HB. Activation of canonical wnt pathway promotes differentiation of mouse bone marrow-derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro. *J Cell Physiol* 2013; **228**: 1270-1283 [PMID: 23154940 DOI: 10.1002/jcp.24282]

124 **Shi C**, Lv T, Xiang Z, Sun Z, Qian W, Han X. Role of Wnt/β-Catenin Signaling in Epithelial Differentiation of Lung Resident Mesenchymal Stem Cells. *J Cell Biochem* 2015; **116**: 1532-1539 [PMID: 25546504 DOI: 10.1002/jcb.25069]

125 **Fang S**, Zhang S, Dai H, Hu X, Li C, Xing Y. The role of pulmonary mesenchymal cells in airway epithelium regeneration during injury repair. *Stem Cell Res Ther* 2019; **10**: 366 [PMID: 31791401 DOI: 10.1186/s13287-019-1452-1]

126 **Tong L**, Zhou J, Rong L, Seeley EJ, Pan J, Zhu X, Liu J, Wang Q, Tang X, Qu J, Bai C, Song Y. Fibroblast Growth Factor-10 (FGF-10) Mobilizes Lung-resident Mesenchymal Stem Cells and Protects Against Acute Lung Injury. *Sci Rep* 2016; **6**: 21642 [PMID: 26869337 DOI: 10.1038/srep21642]

127 **Chen X**, Zhao C, Zhang C, Li Q, Chen J, Cheng L, Zhou J, Su X, Song Y. Vagal-α7nAChR signaling promotes lung stem cells regeneration *via* fibroblast growth factor 10 during lung injury repair. *Stem Cell Res Ther* 2020; **11**: 230 [PMID: 32522255 DOI: 10.1186/s13287-020-01757-w]

128 **Silva JD**, Lopes-Pacheco M, Paz AHR, Cruz FF, Melo EB, de Oliveira MV, Xisto DG, Capelozzi VL, Morales MM, Pelosi P, Cirne-Lima E, Rocco PRM. Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome. *Crit Care Med* 2018; **46**: e132-e140 [PMID: 29116998 DOI: 10.1097/CCM.0000000000002833]

129 **Song CH**, Honmou O, Furuoka H, Horiuchi M. Identification of chemoattractive factors involved in the migration of bone marrow-derived mesenchymal stem cells to brain lesions caused by prions. *J Virol* 2011; **85**: 11069-11078 [PMID: 21813601 DOI: 10.1128/JVI.05318-11]

130 **Larocca TF**, Souza BS, Silva CA, Kaneto CM, Alcantara AC, Azevedo CM, Castro MF, Macambira SG, Soares MB, Ribeiro-dos-Santos R. Transplantation of adipose tissue mesenchymal stem cells in experimental chronic chagasic cardiopathy. *Arq Bras Cardiol* 2013; **100**: 460-468 [PMID: 23568098 DOI: 10.5935/abc.20130058]

131 **Silva DN**, de Freitas Souza BS, Azevedo CM, Vasconcelos JF, Carvalho RH, Soares MB, Dos Santos RR. Intramyocardial transplantation of cardiac mesenchymal stem cells reduces myocarditis in a model of chronic Chagas disease cardiomyopathy. *Stem Cell Res Ther* 2014; **5**: 81 [PMID: 24984860 DOI: 10.1186/scrt470]

132 **Hammam OA**, Elkhafif N, Attia YM, Mansour MT, Elmazar MM, Abdelsalam RM, Kenawy SA, El-Khatib AS. Wharton's jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni-induced liver fibrosis. *Sci Rep* 2016; **6**: 21005 [PMID: 26876222 DOI: 10.1038/srep21005]

133 **Xu H**, Qian H, Zhu W, Zhang X, Yan Y, Mao F, Wang M, Xu H, Xu W. Mesenchymal stem cells relieve fibrosis of Schistosoma japonicum-induced mouse liver injury. *Exp Biol Med (Maywood)* 2012; **237**: 585-592 [PMID: 22678013 DOI: 10.1258/ebm.2012.011362]

134 **Zanganeh E**, Soudi S, Zavaran Hosseini A, Khosrojerdi A. Repeated intravenous injection of adipose tissue derived mesenchymal stem cells enhances Th1 immune responses in Leishmania major-infected BALB/c mice. *Immunol Lett* 2019; **216**: 97-105 [PMID: 31622634 DOI: 10.1016/j.imlet.2019.10.008]

135 **Bulut Ö**, GÜrsel İ. Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection. *Turk J Biol* 2020; **44**: 273-282 [PMID: 32595362 DOI: 10.3906/biy-2002-79]

136 **Harrell CR**, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. *Cells* 2019; **8** [PMID: 31835680 DOI: 10.3390/cells8121605]

137 **Larabi A**, Barnich N, Nguyen HTT. Emerging Role of Exosomes in Diagnosis and Treatment of Infectious and Inflammatory Bowel Diseases. *Cells* 2020; **9** [PMID: 32365813 DOI: 10.3390/cells9051111]

138 **Mardpour S**, Hamidieh AA, Taleahmad S, Sharifzad F, Taghikhani A, Baharvand H. Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. *J Cell Physiol* 2019; **234**: 8249-8258 [PMID: 30378105 DOI: 10.1002/jcp.27669]

139 **Wang J**, Huang R, Xu Q, Zheng G, Qiu G, Ge M, Shu Q, Xu J. Mesenchymal Stem Cell-Derived Extracellular Vesicles Alleviate Acute Lung Injury Via Transfer of miR-27a-3p. *Crit Care Med* 2020; **48**: e599-e610 [PMID: 32317602 DOI: 10.1097/CCM.0000000000004315]

140 **Song Y**, Dou H, Li X, Zhao X, Li Y, Liu D, Ji J, Liu F, Ding L, Ni Y, Hou Y. Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1β-Primed Mesenchymal Stem Cells Against Sepsis. *Stem Cells* 2017; **35**: 1208-1221 [PMID: 28090688 DOI: 10.1002/stem.2564]

141 **Varkouhi AK**, Jerkic M, Ormesher L, Gagnon S, Goyal S, Rabani R, Masterson C, Spring C, Chen PZ, Gu FX, Dos Santos CC, Curley GF, Laffey JG. Extracellular Vesicles from Interferon-γ-primed Human Umbilical Cord Mesenchymal Stromal Cells Reduce Escherichia coli-induced Acute Lung Injury in Rats. *Anesthesiology* 2019; **130**: 778-790 [PMID: 30870158 DOI: 10.1097/ALN.0000000000002655]

142 **Zhu YG**, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A, Qu JM, Matthay MA, Lee JW. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. *Stem Cells* 2014; **32**: 116-125 [PMID: 23939814 DOI: 10.1002/stem.1504]

143 **Hao Q**, Gudapati V, Monsel A, Park JH, Hu S, Kato H, Lee JH, Zhou L, He H, Lee JW. Mesenchymal Stem Cell-Derived Extracellular Vesicles Decrease Lung Injury in Mice. *J Immunol* 2019; **203**: 1961-1972 [PMID: 31451675 DOI: 10.4049/jimmunol.1801534]

144 **Saeki K**, Yokomizo T. Identification, signaling, and functions of LTB4 receptors. *Semin Immunol* 2017; **33**: 30-36 [PMID: 29042026 DOI: 10.1016/j.smim.2017.07.010]

145 **Stone ML**, Zhao Y, Robert Smith J, Weiss ML, Kron IL, Laubach VE, Sharma AK. Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death. *Respir Res* 2017; **18**: 212 [PMID: 29268735 DOI: 10.1186/s12931-017-0704-9]

146 **Wang H**, Zheng R, Chen Q, Shao J, Yu J, Hu S. Mesenchymal stem cells microvesicles stabilize endothelial barrier function partly mediated by hepatocyte growth factor (HGF). *Stem Cell Res Ther* 2017; **8**: 211 [PMID: 28969681 DOI: 10.1186/s13287-017-0662-7]

147 **Khatri M**, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. *Stem Cell Res Ther* 2018; **9**: 17 [PMID: 29378639 DOI: 10.1186/s13287-018-0774-8]

148 **Qian X**, Xu C, Fang S, Zhao P, Wang Y, Liu H, Yuan W, Qi Z. Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection. *Stem Cells Transl Med* 2016; **5**: 1190-1203 [PMID: 27496568 DOI: 10.5966/sctm.2015-0348]

149 **Zhao S**, Liu Y, Pu Z. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro. *Drug Des Devel Ther* 2019; **13**: 2887-2897 [PMID: 31695322 DOI: 10.2147/DDDT.S220190]

150 **Gu X**, Li Y, Chen K, Wang X, Wang Z, Lian H, Lin Y, Rong X, Chu M, Lin J, Guo X. Exosomes derived from umbilical cord mesenchymal stem cells alleviate viral myocarditis through activating AMPK/mTOR-mediated autophagy flux pathway. *J Cell Mol Med* 2020; **24**: 7515-7530 [PMID: 32424968 DOI: 10.1111/jcmm.15378]

151 **Deffune E**, Prudenciatti A, Moroz A. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients. *Med Hypotheses* 2020; **142**: 109769 [PMID: 32371362 DOI: 10.1016/j.mehy.2020.109769]

152 **Su VY**, Lin CS, Hung SC, Yang KY. Mesenchymal Stem Cell-Conditioned Medium Induces Neutrophil Apoptosis Associated with Inhibition of the NF-κB Pathway in Endotoxin-Induced Acute Lung Injury. *Int J Mol Sci* 2019; **20** [PMID: 31060326 DOI: 10.3390/ijms20092208]

153 **Asami T**, Ishii M, Namkoong H, Yagi K, Tasaka S, Asakura T, Suzuki S, Kamo T, Okamori S, Kamata H, Zhang H, Hegab AE, Hasegawa N, Betsuyaku T. Anti-inflammatory roles of mesenchymal stromal cells during acute Streptococcus pneumoniae pulmonary infection in mice. *Cytotherapy* 2018; **20**: 302-313 [PMID: 29397306 DOI: 10.1016/j.jcyt.2018.01.003]

154 **Hayes M**, Curley GF, Masterson C, Devaney J, O'Toole D, Laffey JG. Mesenchymal stromal cells are more effective than the MSC secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury. *Intensive Care Med Exp* 2015; **3**: 29 [PMID: 26472334 DOI: 10.1186/s40635-015-0065-y]

155 **Park J**, Kim S, Lim H, Liu A, Hu S, Lee J, Zhuo H, Hao Q, Matthay MA, Lee JW. Therapeutic effects of human mesenchymal stem cell microvesicles in an *ex vivo* perfused human lung injured with severe *E. coli* pneumonia. *Thorax* 2019; **74**: 43-50 [PMID: 30076187 DOI: 10.1136/thoraxjnl-2018-211576]

156 **Martínez-González I**, Roca O, Masclans JR, Moreno R, Salcedo MT, Baekelandt V, Cruz MJ, Rello J, Aran JM. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. *Am J Respir Cell Mol Biol* 2013; **49**: 552-562 [PMID: 23656573 DOI: 10.1165/rcmb.2012-0406OC]

157 **Chan BCL**, Lam CWK, Tam LS, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. *Front Immunol* 2019; **10**: 364 [PMID: 30886621 DOI: 10.3389/fimmu.2019.00364]

158 **Chen X**, Wu S, Tang L, Ma L, Wang F, Feng H, Meng J, Han Z. Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats. *J Cell Physiol* 2019; **234**: 7301-7319 [PMID: 30362554 DOI: 10.1002/jcp.27488]

159 **Mei SH**, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. *PLoS Med* 2007; **4**: e269 [PMID: 17803352 DOI: 10.1371/journal.pmed.0040269]

160 **Chen J**, Zhang X, Xie J, Xue M, Liu L, Yang Y, Qiu H. Overexpression of TGFβ1 in murine mesenchymal stem cells improves lung inflammation by impacting the Th17/Treg balance in LPS-induced ARDS mice. *Stem Cell Res Ther* 2020; **11**: 311 [PMID: 32698911 DOI: 10.1186/s13287-020-01826-0]

161 **Zhao YF**, Luo YM, Xiong W, Ding W, Li YR, Zhao W, Zeng HZ, Gao HC, Wu XL. Mesenchymal stem cell-based FGF2 gene therapy for acute lung injury induced by lipopolysaccharide in mice. *Eur Rev Med Pharmacol Sci* 2015; **19**: 857-865 [PMID: 25807440]

162 **Zhao YF**, Xiong W, Wu XL. Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. *Mol Med Rep* 2014; **9**: 1583-1589 [PMID: 24573341 DOI: 10.3892/mmr.2014.1988]

163 **Meng SS**, Guo FM, Zhang XW, Chang W, Peng F, Qiu HB, Yang Y. mTOR/STAT-3 pathway mediates mesenchymal stem cell-secreted hepatocyte growth factor protective effects against lipopolysaccharide-induced vascular endothelial barrier dysfunction and apoptosis. *J Cell Biochem* 2019; **120**: 3637-3650 [PMID: 30242894 DOI: 10.1002/jcb.27642]

164 **Zhang X**, Chen J, Xue M, Tang Y, Xu J, Liu L, Huang Y, Yang Y, Qiu H, Guo F. Overexpressing p130/E2F4 in mesenchymal stem cells facilitates the repair of injured alveolar epithelial cells in LPS-induced ARDS mice. *Stem Cell Res Ther* 2019; **10**: 74 [PMID: 30841904 DOI: 10.1186/s13287-019-1169-1]

165 **Imai Y**, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005; **436**: 112-116 [PMID: 16001071 DOI: 10.1038/nature03712]

166 **He H**, Liu L, Chen Q, Liu A, Cai S, Yang Y, Lu X, Qiu H. Mesenchymal Stem Cells Overexpressing Angiotensin-Converting Enzyme 2 Rescue Lipopolysaccharide-Induced Lung Injury. *Cell Transplant* 2015; **24**: 1699-1715 [PMID: 25291359 DOI: 10.3727/096368914X685087]

167 **Li W**, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003; **426**: 450-454 [PMID: 14647384 DOI: 10.1038/nature02145]

168 **Ni W**, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. *Crit Care* 2020; **24**: 422 [PMID: 32660650 DOI: 10.1186/s13054-020-03120-0]

169 **Yang JX**, Zhang N, Wang HW, Gao P, Yang QP, Wen QP. CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats. *J Biol Chem* 2015; **290**: 1994-2006 [PMID: 25492872 DOI: 10.1074/jbc.M114.605063]

170 **Han J**, Lu X, Zou L, Xu X, Qiu H. E-Prostanoid 2 Receptor Overexpression Promotes Mesenchymal Stem Cell Attenuated Lung Injury. *Hum Gene Ther* 2016; **27**: 621-630 [PMID: 27158855 DOI: 10.1089/hum.2016.003]

171 **Almeida CR**, Caires HR, Vasconcelos DP, Barbosa MA. NAP-2 Secreted by Human NK Cells Can Stimulate Mesenchymal Stem/Stromal Cell Recruitment. *Stem Cell Reports* 2016; **6**: 466-473 [PMID: 27052313 DOI: 10.1016/j.stemcr.2016.02.012]

172 **Shen Z**, Wang J, Huang Q, Shi Y, Wei Z, Zhang X, Qiu Y, Zhang M, Wang Y, Qin W, Huang S, Huang Y, Liu X, Xia K, Zhang X, Lin Z. Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositis. *Cell Death Dis* 2018; **9**: 229 [PMID: 29445104 DOI: 10.1038/s41419-018-0310-x]

173 **Bustos ML**, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sciurba JD, Mroz L, McVerry BJ, Ellis BM, Kaminski N, Rojas M. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. *Stem Cells Transl Med* 2013; **2**: 884-895 [PMID: 24089414 DOI: 10.5966/sctm.2013-0033]

174 **Rodriguez LA 2nd**, Mohammadipoor A, Alvarado L, Kamucheka RM, Asher AM, Cancio LC, Antebi B. Preconditioning in an Inflammatory Milieu Augments the Immunotherapeutic Function of Mesenchymal Stromal Cells. *Cells* 2019; **8** [PMID: 31096722 DOI: 10.3390/cells8050462]

175 **Saldaña L**, Bensiamar F, Vallés G, Mancebo FJ, García-Rey E, Vilaboa N. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. *Stem Cell Res Ther* 2019; **10**: 58 [PMID: 30760316 DOI: 10.1186/s13287-019-1156-6]

176 **Li D**, Liu Q, Qi L, Dai X, Liu H, Wang Y. Low levels of TGF-β1 enhance human umbilical cord-derived mesenchymal stem cell fibronectin production and extend survival time in a rat model of lipopolysaccharide-induced acute lung injury. *Mol Med Rep* 2016; **14**: 1681-1692 [PMID: 27357811 DOI: 10.3892/mmr.2016.5416]

177 **Silva JD**, Lopes-Pacheco M, de Castro LL, Kitoko JZ, Trivelin SA, Amorim NR, Capelozzi VL, Morales MM, Gutfilen B, de Souza SAL, Weiss DJ, Diaz BL, Rocco PRM. Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis. *Stem Cell Res Ther* 2019; **10**: 264 [PMID: 31443678 DOI: 10.1186/s13287-019-1365-z]

178 **Spaggiari GM**, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* 2006; **107**: 1484-1490 [PMID: 16239427 DOI: 10.1182/blood-2005-07-2775]

179 **Masalova OV**, Lesnova EI, Klimova RR, Momotyuk ED, Kozlov VV, Ivanova AM, Payushina OV, Butorina NN, Zakirova NF, Narovlyansky AN, Pronin AV, Ivanov AV, Kushch AA. Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response. *Vaccines (Basel)* 2020; **8** [PMID: 32024236 DOI: 10.3390/vaccines8010062]

180 **Meng SS**, Xu XP, Chang W, Lu ZH, Huang LL, Xu JY, Liu L, Qiu HB, Yang Y, Guo FM. LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning. *Stem Cell Res Ther* 2018; **9**: 280 [PMID: 30359325 DOI: 10.1186/s13287-018-1031-x]

181 **Antebi B**, Rodriguez LA 2nd, Walker KP 3rd, Asher AM, Kamucheka RM, Alvarado L, Mohammadipoor A, Cancio LC. Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells. *Stem Cell Res Ther* 2018; **9**: 265 [PMID: 30305185 DOI: 10.1186/s13287-018-1007-x]

182 **Liu L**, He H, Liu A, Xu J, Han J, Chen Q, Hu S, Xu X, Huang Y, Guo F, Yang Y, Qiu H. Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Models of Pulmonary and Extrapulmonary Acute Lung Injury. *Cell Transplant* 2015; **24**: 2629-2642 [PMID: 25695285 DOI: 10.3727/096368915X687499]

183 **Xu L**, Gong Y, Wang B, Shi K, Hou Y, Wang L, Lin Z, Han Y, Lu L, Chen D, Lin X, Zeng Q, Feng W, Chen Y. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. *J Gastroenterol Hepatol* 2014; **29**: 1620-1628 [PMID: 24942592 DOI: 10.1111/jgh.12653]

184 **Fang X**, Liu L, Dong J, Zhang J, Song H, Song Y, Huang Y, Cui X, Lin J, Chen C, Liu B, Chen Z, Pan J, Chen X. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis. *J Gastroenterol Hepatol* 2018; **33**: 774-780 [PMID: 29293276 DOI: 10.1111/jgh.14081]

185 **Xu WX**, He HL, Pan SW, Chen YL, Zhang ML, Zhu S, Gao ZL, Peng L, Li JG. Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China. *Stem Cells Int* 2019; **2019**: 4130757 [PMID: 30863450 DOI: 10.1155/2019/4130757]

186 **Jia Y**, Shu X, Yang X, Sun H, Cao H, Cao H, Zhang K, Xu Q, Li G, Yang Y. Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis. *Stem Cell Res Ther* 2020; **11**: 277 [PMID: 32650827 DOI: 10.1186/s13287-020-01787-4]

187 **Salama H**, Zekri AR, Medhat E, Al Alim SA, Ahmed OS, Bahnassy AA, Lotfy MM, Ahmed R, Musa S. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. *Stem Cell Res Ther* 2014; **5**: 70 [PMID: 24886681 DOI: 10.1186/scrt459]

188 **CDC**. Middle East Respiratory Syndrome (MERS). 2019 [cited 5 March 2021]. In: Centers for Disease Control and Prevention [Internet]. Available from: https://www.cdc.gov/coronavirus/mers/about/index.html

189 **CDC**. Influenza Type A Viruses, Avian Influenza (Flu); 2017. [cited 5 March 2021]. In: Centers for Disease Control and Prevention [Internet]. Available from: https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm

190 **WHO**. Avian influenza: food safety issues; 2006. [cited 5 March 2021]. In: World Health Organization [Internet]. Available from: https://www.who.int/foodsafety/areas\_work/zoonose/avian/en/index1.html

191 **Chen J**, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L, Dai X, Xiang C, Li L. Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. *Engineering (Beijing)* 2020; **6**: 1153-1161 [PMID: 32292627 DOI: 10.1016/j.eng.2020.02.006]

192 **Simonson OE**, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dalén M, Jitschin R, Rodin S, Corbascio M, El Andaloussi S, Wiklander OP, Nordin JZ, Skog J, Romain C, Koestler T, Hellgren-Johansson L, Schiller P, Joachimsson PO, Hägglund H, Mattsson M, Lehtiö J, Faridani OR, Sandberg R, Korsgren O, Krampera M, Weiss DJ, Grinnemo KH, Le Blanc K. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. *Stem Cells Transl Med* 2015; **4**: 1199-1213 [PMID: 26285659 DOI: 10.5966/sctm.2015-0021]

193 **Leng Z**, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. *Aging Dis* 2020; **11**: 216-228 [PMID: 32257537 DOI: 10.14336/AD.2020.0228]

194 **Zhang Y**, Ding J, Ren S, Wang W, Yang Y, Li S, Meng M, Wu T, Liu D, Tian S, Tian H, Chen S, Zhou C. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. *Stem Cell Res Ther* 2020; **11**: 207 [PMID: 32460839 DOI: 10.1186/s13287-020-01725-4]

195 **Peng H**, Gong T, Huang X, Sun X, Luo H, Wang W, Luo J, Luo B, Chen Y, Wang X, Long H, Mei H, Li C, Dai Y, Li H. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. *Stem Cell Res Ther* 2020; **11**: 291 [PMID: 32678017 DOI: 10.1186/s13287-020-01802-8]

196 **Du J**, Li H, Lian J, Zhu X, Qiao L, Lin J. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury. *Stem Cell Res Ther* 2020; **11**: 192 [PMID: 32448377 DOI: 10.1186/s13287-020-01699-3]

197 **Golchin A**, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. *Stem Cell Rev Rep* 2020; **16**: 427-433 [PMID: 32281052 DOI: 10.1007/s12015-020-09973-w]

198 **Rogers CJ**, Harman RJ, Bunnell BA, Schreiber MA, Xiang C, Wang FS, Santidrian AF, Minev BR. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. *J Transl Med* 2020; **18**: 203 [PMID: 32423449 DOI: 10.1186/s12967-020-02380-2]

199 **Moll G**, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. *Front Immunol* 2020; **11**: 1091 [PMID: 32574263 DOI: 10.3389/fimmu.2020.01091]

200 **Chen X**, Shan Y, Wen Y, Sun J, Du H. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects. *J Infect* 2020; **81**: 647-679 [PMID: 32422152 DOI: 10.1016/j.jinf.2020.05.020]

201 **Naik SK**, Padhi A, Ganguli G, Sengupta S, Pati S, Das D, Sonawane A. Mouse Bone Marrow Sca-1+ CD44+ Mesenchymal Stem Cells Kill Avirulent Mycobacteria but Not Mycobacterium tuberculosis through Modulation of Cathelicidin Expression *via* the p38 Mitogen-Activated Protein Kinase-Dependent Pathway. *Infect Immun* 2017; **85** [PMID: 28739828 DOI: 10.1128/iai.00471-17]

202 **Jain N**, Kalam H, Singh L, Sharma V, Kedia S, Das P, Ahuja V, Kumar D. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis. *Nat Commun* 2020; **11**: 3062 [PMID: 32546788 DOI: 10.1038/s41467-020-16877-3]

203 **Lopes CS**, Daifalla N, Das B, Dias da Silva V, Campos-Neto A. CD271+ Mesenchymal Stem Cells as a Possible Infectious Niche for Leishmania infantum. *PLoS One* 2016; **11**: e0162927 [PMID: 27622907 DOI: 10.1371/journal.pone.0162927]

204 **Qiao GH**, Zhao F, Cheng S, Luo MH. Multipotent mesenchymal stromal cells are fully permissive for human cytomegalovirus infection. *Virol Sin* 2016; **31**: 219-228 [PMID: 27105639 DOI: 10.1007/s12250-016-3754-0]

205 **Soland MA**, Keyes LR, Bayne R, Moon J, Porada CD, St Jeor S, Almeida-Porada G. Perivascular stromal cells as a potential reservoir of human cytomegalovirus. *Am J Transplant* 2014; **14**: 820-830 [PMID: 24592822 DOI: 10.1111/ajt.12642]

206 **Meisel R**, Heseler K, Nau J, Schmidt SK, Leineweber M, Pudelko S, Wenning J, Zimmermann A, Hengel H, Sinzger C, Degistirici Ö, Sorg RV, Däubener W. Cytomegalovirus infection impairs immunosuppressive and antimicrobial effector functions of human multipotent mesenchymal stromal cells. *Mediators Inflamm* 2014; **2014**: 898630 [PMID: 24782599 DOI: 10.1155/2014/898630]

207 **Sundin M**, Lindblom A, Örvell C, Barrett AJ, Sundberg B, Watz E, Wikman A, Broliden K, Le Blanc K. Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation. *Biol Blood Marrow Transplant* 2008; **14**: 1172-1179 [PMID: 18804048 DOI: 10.1016/j.bbmt.2008.08.003]

208 **Avanzi S**, Leoni V, Rotola A, Alviano F, Solimando L, Lanzoni G, Bonsi L, Di Luca D, Marchionni C, Alvisi G, Ripalti A. Susceptibility of human placenta derived mesenchymal stromal/stem cells to human herpesviruses infection. *PLoS One* 2013; **8**: e71412 [PMID: 23940750 DOI: 10.1371/journal.pone.0071412]

209 **Ma R**, Xing Q, Shao L, Wang D, Hao Q, Li X, Sai L, Ma L. Hepatitis B virus infection and replication in human bone marrow mesenchymal stem cells. *Virol J* 2011; **8**: 486 [PMID: 22035170 DOI: 10.1186/1743-422X-8-486]

210 **Wang Y**, Wang F, Zhao H, Zhang X, Chen H, Zhang K. Human adipose-derived mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vitro. *Int J Mol Sci* 2014; **15**: 6096-6110 [PMID: 24727377 DOI: 10.3390/ijms15046096]

211 **Thanunchai M**, Kanrai P, Wiboon-Ut S, Puthavathana P, Hongeng S, Thitithanyanont A. Tropism of avian influenza A (H5N1) virus to mesenchymal stem cells and CD34+ hematopoietic stem cells. *PLoS One* 2013; **8**: e81805 [PMID: 24339969 DOI: 10.1371/journal.pone.0081805]

212 **Cotter EJ**, Chew N, Powderly WG, Doran PP. HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. *AIDS Res Hum Retroviruses* 2011; **27**: 187-199 [PMID: 20929345 DOI: 10.1089/aid.2010.0114]

213 **Cheng K**, Rai P, Lan X, Plagov A, Malhotra A, Gupta S, Singhal PC. Bone-derived mesenchymal stromal cells from HIV transgenic mice exhibit altered proliferation, differentiation capacity and paracrine functions along with impaired therapeutic potential in kidney injury. *Exp Cell Res* 2013; **319**: 2266-2274 [PMID: 23806280 DOI: 10.1016/j.yexcr.2013.06.008]

214 **Cervenakova L**, Akimov S, Vasilyeva I, Yakovleva O, McKenzie C, Cervenak J, Piccardo P, Asher DM. Fukuoka-1 strain of transmissible spongiform encephalopathy agent infects murine bone marrow-derived cells with features of mesenchymal stem cells. *Transfusion* 2011; **51**: 1755-1768 [PMID: 21303371 DOI: 10.1111/j.1537-2995.2010.03041.x]

215 **Berglund AK**, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. *Stem Cell Res Ther* 2017; **8**: 288 [PMID: 29273086 DOI: 10.1186/s13287-017-0742-8]

216 **Consentius C**, Reinke P, Volk HD. Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen *in vitro* and in vivo? *Regen Med* 2015; **10**: 305-315 [PMID: 25933239 DOI: 10.2217/rme.15.14]

217 **Griffin MD**, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? *Immunol Cell Biol* 2013; **91**: 40-51 [PMID: 23207278 DOI: 10.1038/icb.2012.67]

218 **Berebichez-Fridman R**, Montero-Olvera PR. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. *Sultan Qaboos Univ Med J* 2018; **18**: e264-e277 [PMID: 30607265 DOI: 10.18295/squmj.2018.18.03.002]

219 **Miteva K**, Pappritz K, Sosnowski M, El-Shafeey M, Müller I, Dong F, Savvatis K, Ringe J, Tschöpe C, Van Linthout S. Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. *Sci Rep* 2018; **8**: 2820 [PMID: 29434214 DOI: 10.1038/s41598-018-20686-6]

220 **Chen X**, Zhang Y, Wang W, Liu Z, Meng J, Han Z. Mesenchymal Stem Cells Modified with Heme Oxygenase-1 Have Enhanced Paracrine Function and Attenuate Lipopolysaccharide-Induced Inflammatory and Oxidative Damage in Pulmonary Microvascular Endothelial Cells. *Cell Physiol Biochem* 2018; **49**: 101-122 [PMID: 30153667 DOI: 10.1159/000492847]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 8, 2021

**First decision:** March 29, 2021

**Article in press:**

**Specialty type:** Infectious diseases

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Liu L, Mousa HAL **S-Editor:** Liu M **L-Editor:** Filipodia **P-Editor:**


**Figure Legends**




**Figure 1 Direct bacterial lysis and phagocytosis.** Secretion of antimicrobial peptides such as LL-37, β-defensin 2 (BD2), lipocalin 2 (LCN2), hepcidin antimicrobial peptide (HAMP), and indoleamine 2, 3-dioxygenase (IDO) by mesenchymal stem cells (MSCs) have bactericidal effects[23,24,30,31]. LCN2 and HAMP inhibit iron (Fe) uptake by bacterial cells, and IDO inhibits the uptake of the essential amino acid tryptophan (Trp), leading to growth inhibition and death of bacterial cells[27,29]. MSCs can also directly phagocytose bacteria[32].



**Figure 2 Immunomodulation by mesenchymal stem cells.** Mesenchymal stem cells (MSCs) secrete various paracrine factors and chemokines to reduce inflammation at the site of injury by inhibiting infiltration of neutrophils, pro-inflammatory monocytes, and maturation of dendritic cells[39,62,219]. MSCs promote anti-inflammatory M2 phenotype in macrophages, improve phagocytic ability and increase their survival *via* mitochondrial transfer[12,43-45,48]. MSCs under inflammatory conditions inhibit T-cell proliferation *via* secretion of programmed death-ligand 1 (PD-L1) and PD-L2[54]. MSCs induce a “tolerogenic” phenotype in monocytes and promote migration of regulatory T cells to the site of infection[58,60]. Ang1: Angiopoietin-1; EVs: Extracellular vesicles; HGF: Hepatocyte growth factor; KGF: Keratinocyte growth factor; LXA: LipoxinA4; MMPs: Matrix metalloproteinases; VEGF: Vascular endothelial growth factor.



**Figure 3 Tissue repair and regeneration.** Mesenchymal stem cells (MSCs) have multilineage differentiation potential and can differentiate into cells of target tissue during injury. MSCs also reduce collagen deposition and fibrosis at the site of injury by secreting matrix metalloproteinases[114,115]. Mitogens secreted directly or packaged in extracellular vesicles secreted by MSCs, mitochondrial transfer from MSCs to the injured cells promote proliferation and survival of lung epithelial cells[87,88]. MSCs also secrete pro-angiogenic factors such as vascular endothelial growth factor[108] and LL-37 to promote angiogenesis[25]. In the context of lung injury, lipoxinA4, angiopoietin-1, keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor promote alveolar fluid clearance, which improves gas exchange in the lungs[68,70,94,95]. CXCL: C-X-C motif ligand; DC: Dendritic cell; HGF: Human growth factor; HO-1: Heme oxgenase-1; IFNγ: Interferon γ; IL-10: Interleukin 10; IL1RA: Interleukin 1 receptor antagonist; PD-L1: Programmed death-ligand 1; PGE: Prostaglandin E2; ROS: Reactive oxygen species; SOD: Superoxide dismutase; SP: Surfactant protein; STC: Stanniocalcin; TSG-6: Tumor necrosis factor α-stimulated gene-6; TNFα: Tumor necrosis factor α; TGF: Transforming growth factor; Treg: regulatory T cell; TSP: Thrombospondin.



**Figure 4 Signaling pathways modified by mesenchymal stem cells in alveolar lung epithelial cells during lung injury.** Mesenchymal stem cells (MSCs) reduce alveolar permeability and promote survival of alveolar epithelial cells through secretion of lipoxinA4 (LXA4), angiopoietin (Ang1), keratinocyte growth factor (KGF), along with extracellular vesicles (EVs). During acute lung injury (ALI), LXA4 inhibits apoptosis of alveolar epithelial cells by inhibiting caspase-3[104]. LXA4 also upregulates ion channels like Na+/K+ pump and rescues expression of cystic fibrosis transmembrane conductance regulator and epithelial Na+ channel by inhibiting Akt phosphorylation[96]. LXA4 also rescues E-cadherin expression by reducing reactive oxygen species *via* modulation of nuclear factor erythroid 2–related factor 2/heme oxygenase-1 expression[103]. LXA4, as well as Ang1, promote the expression of tight junction proteins like occludin, Zona occludens, and claudin 1[64,94,100]. Ang1 also rescues the expression of claudin 18 by inhibiting NF-κB. Ang1 upregulates Rac1, which promotes the formation of adherens and tight junctions[106]. KGF promotes the secretion of surfactant protein SP-A by alveolar epithelial cells and promotes the expression of Na+/K+ pump[87]. Inhibition of mTOR by miR-100 present in EVs secreted by MSCs increases autophagy, thereby promotes survival of epithelial cells during ALI. Ca2+ dependent transfer of mitochondria from MSCs, through gap junctions formed by Cx43, increases ATP generation in epithelial cells and improves their survival[112]. Akt: Protein kinase B; Ang1: Angiopoietin; AQP5: Aquaporin-5; ATP: Adenosine triphosphate; Cas3: Caspase-3; CFTR: Cystic fibrosis transmembrane conductance regulator; CLD1: Claudin 1; ENaC: Epithelial Na+ channel; EVs: Extracellular vesicles; HO-1: Heme oxygenase-1;KGF: Keratinocyte growth factor; LXA4: LipoxinA4; MSC: Mesenchymal stem cell; mTOR: Mammalian target of rapamycin; NF-κB: Nuclear factor-kappa B; Nrf2: Nuclear factor erythroid 2-related factor 2; OCLD: Occludin; Rac1: Rac family small GTPase 1; RhoA: Ras homolog family member A; ROS: Reactive oxygen species; ZO-1: Zona occludens.

**Table 1 Genetic modifications to enhance mesenchymal stem cells potential for treatment of infectious diseases and associated tissue injury**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Overexpressed genes** | | **Source of MSCs** | **Disease model** | **Experimental Outcome** | **Ref.** |
| sST2, Ang1, HO1 | | Human AD-MSCs, Mice BM-MSCs | LPS-induced ALI mouse model | Improved preservation of lung architecture and reduced inflammation | Xu *et al*[77], Martínez-González *et al*[156], Mei *et al*[159], Chen *et al*[160], and Chen *et al*[220] |
| TGF-β1 | | Mice BM-MSCs | LPS-induced ARDS mice | Increased Treg, induced occludin expression and reduced vascular permeability | Chen *et al*[160] |
| IL-10 | | Human UC-MSCs | *E. coli*-induced pneumosepsis mouse model | Reduced bacterial load by increasing phagocytosis in macrophages | Jerkic *et al*[75] |
| Del-1, FGF2 | Mice BM-MSCs | LPS-induced ALI mouse model | Reduction in inflammation and lung injury | Zhao *et al*[161], Zhao *et al*[161,162] |
| HGF | Mice BM-MSCs | *In vitro* LPS treatment of pulmonary endothelial cells | Upregulated occludin and reduced permeability | Meng *et al*[163] |
| β-catenin, ROR2, p130/E2F4 | Mice BM-MSCs | LPS-induced ARDS mouse model | Higher retention in lungs and increased differentiation into AT II cells | Cai *et al* [114], Cai *et al*[121], Zhang *et al*[114,121,164] |
| ACE2 | Mice BM-MSCs | LPS-induced ALI mouse model | Reduced permeability and lung Ang-II levels | He *et al*[166] |
| CXCR4, EP2 CXCR2 | Mice BM-MSCs | ALI/ARDS mouse model | Increased homing to the site of injury | Yang *et al* [169], Han *et al*[170], Shen *et al*[169-171] |

ACE2: Angiotensin-converting enzyme 2; AD-MSCs: Adipose tissue-derived mesenchymal stem cells; ALI: Acute lung injury; Ang1: Angiopoietin-1; ARDS: Acute respiratory distress syndrome; AT II: Alveolar epithelial cell type II; BM-MSCs: Bone marrow-derived mesenchymal stem cells; CXCR: (C-X-C motif) chemokine receptor; Del-1: Developmental endothelial locus-1; E2F4: E2F Transcription Factor 4; EP2: E-prostanoid receptor 2; FGF-2: Fibroblast growth factor 2; HGF: Hepatocyte growth factor; HO1: Heme oxygenase-1; IL-10: Interleukin 10; LPS: Lipopolysaccharides; MSCs: Mesenchymal stem cells; p130: Retinoblastoma-related protein 2; ROR2: Receptor tyrosine kinase-like orphan receptor 2; sST2: Soluble IL-1 receptor-like 1; TGF-β: Transforming growth factor-β; Treg: Regulatory T cell.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**